LPA1 small molecule antagonist
Novel LPA1 small molecule antagonists, characterized by specific chemical structures, address the lack of effective treatments for LPA-mediated diseases by inhibiting LPA receptor binding, providing therapeutic modulation of cellular signaling pathways.
Patent Information
- Application Number
- JP2026196510
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-02
- Filing Date
- 2026-08-28
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for diseases and disorders mediated by LPA receptors lack effective small molecule antagonists that can modulate the biological responses induced by lysophosphatidic acid (LPA) through specific G protein-coupled receptors.
Development of novel LPA1 small molecule antagonists represented by specific chemical compounds and their pharmaceutically acceptable salts, characterized by various substituents and functional groups, which can inhibit the binding of LPA to its receptors, thereby modulating cellular signaling pathways.
The developed LPA1 small molecule antagonists provide a targeted approach to treat diseases and disorders influenced by LPA, offering potential therapeutic benefits by blocking undesirable biological responses.
Smart Images

Figure 2026182898000001 
Figure 2026182898000002 
Figure 2026182898000003
Abstract
Description
[Technical Field]
[0001] This disclosure pertains to the pharmaceutical field and relates to LPA1 small molecule antagonists. [Background technology]
[0002] Serum phospholipids are membrane-derived bioactive lipid mediators, of which lysophosphatidic acid (LPA) is one of the most medically important. Lysophospholipids influence fundamental cellular functions, including proliferation, differentiation, survival, migration, adhesion, invasion, and morphogenesis. These functions affect many biological processes, including, but not limited to, neurogenesis, angiogenesis, wound healing, fibrosis, immunology, and carcinogenesis.
[0003] LPA is not a single molecular entity, but rather an endogenous structural variant possessing a group of fatty acids of varying lengths and saturations. The structural backbone of LPA is derived from glycerol-based phospholipids such as phosphatidylcholine (PC) or phosphatidic acid (PA). Lysophosphatidic acid (LPA) is a lysophospholipid that acts autocrine and paracrinely via a specific group of G protein-coupled receptors (GPCRs). LPA binds to its homologous GPCRs (LPA1, LPA2, LPA3, LPA4, LPA5, LPA6) and generates various biological responses by activating intracellular signaling pathways. LPA receptor antagonists have been found to be applicable to the treatment of diseases, disorders, or conditions on which LPA acts. [Overview of the Initiative]
[0004] In a first embodiment, the present disclosure provides a compound represented by formula I or a pharmaceutically acceptable salt thereof. [ka] Of these, ring C is selected from an 8-15 member cycloalkyl group substituted with a carboxyl group or P(=O)(OH)2. R1 is hydrogen, C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6selected from an alkoxy group, a halogen, a cyano group, a nitro group, a hydroxy group, a 3-6 membered heterocyclyl group, a 5-6 membered heteroaryl group, a -O-3-6 membered heterocyclyl group, and a -O-5-6 membered heteroaryl group, the above C 1-6 alkyl group, a 3-6 membered cycloalkyl group, C 1-6 alkoxy group, 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group are optionally substituted with one or more R 4a , -X- is selected from -CO-NR0-, -CH2-, -Y1-NR0-, -NR0-Y1-, -Y1-O-, -O-Y1-, -S-Y1-, -S(=O)2-Y1-, and -O-C(=O)-NR0-, the above Y1 is selected from a single bond, an alkylene group, and an alkenylene group, the above alkylene group and alkenylene group are optionally substituted with one or more oxo, hydroxy groups, cyano groups, or halogens, and the above R0 is hydrogen, C 1-6 selected from alkyl groups, preferably hydrogen, C 1-6 alkyl group, W is selected from a nitrogen atom or a carbon atom, R2 is hydrogen, C 1-6 alkyl group, C 1-6 selected from an alkoxy group, a hydroxy group, a halogen, a nitro group, a cyano group, an amino group, a carboxy group, a 3-6 membered cycloalkyl group, a 3-6 membered heterocyclyl group, a 5-6 membered heteroaryl group, a -O-3-6 membered heterocyclyl group, and a -O-5-6 membered heteroaryl group, the above C 1-6 alkyl group, C 1-6 alkoxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group are optionally substituted with one to more R 4b , Ring A is selected from a 5-6 membered heteroaryl group, R5 is C 1-6 alkyl group, C 1-6 substituted with a substituent selected from an alkoxy group, a methylenecyclopropyl group, a halogen, a nitro group, and a cyano group, the above C 1-6 alkyl group, C1-6 The alkoxy group and methylenecyclopropyl group are optionally substituted with one or more substituents selected from halogen, hydroxyl, cyano, and nitro groups. Y is selected from either an oxygen atom or a nitrogen atom. Ring B is selected from 5-6 membered heteroaryl groups, and the above 5-6 membered heteroaryl groups are optionally C 1-6 Alkyl alkyl group, C 1-6 Substituted with 1 to 3 substituents selected from alkoxy groups, methylenecyclopropyl groups, halogens, nitro groups, and cyano groups, the above C 1-6 Alkyl alkyl group, C 1-6 The alkoxy group and methylenecyclopropyl group are optionally substituted with one or more substituents selected from halogen, hydroxyl, cyano, and nitro groups. R3 is hydrogen, C 1-6 Alkyl alkyl group, C 1-6 Selected from alkoxy groups, 3-6 membered cycloalkyl groups, 3-6 membered heterocyclyl groups, 5-6 membered heteroaryl groups, -O-3-6 membered heterocyclyl groups, -O-5-6 membered heteroaryl groups, hydroxyl groups, halogens, nitro groups, cyano groups, amino groups, and carboxyl groups, the above C 1-6 Alkyl alkyl group, C 1-6 The alkoxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group can be optionally one to multiple R groups. 4c Replaced by, R 4a , R 4b , R 4c These are, independently, halogen, hydroxyl group, oxo, nitro group, cyano group, amino group, and C 1-6 Alkyl, halo C 1-6 Alkyl alkyl group, C 1-6 Alkoxy group, Halo C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 3-6 membered heterocycloalkoxy group, C 3-8Selected from a cycloalkenyloxy group, a 5-6 membered aryl group, or a 3-6 membered heteroaryl group.
[0005] In some embodiments, in the compound represented by formula I or its medicinal salt, the ring C is substituted with a carboxyl group or P(=O)(OH)2- [ka] They are selected from among them.
[0006] In some embodiments, in the compound represented by formula I or a medicinal salt thereof, ring C is [ka] Selected from, preferably, ring C is [ka] They are selected from among them.
[0007] In some embodiments, in the compound represented by formula I or its medicinal salt, -X- is selected from -CO-NR0-, -CH2-, -Y1-NR0-, -NR0-Y1-, -Y1-O-, -O-Y1-, -S-Y1-, -S(=O)2-Y1-, -OC(=O)-NR0-, The above Y1 is selected from a single bond, an alkylene group, and an alkenylene group, and the above alkylene group and alkenylene group are optionally substituted with one or more oxo, hydroxyl, cyano, or halogen groups. R0 above is hydrogen, C 1-6 Selected from alkyl groups.
[0008] In some embodiments, in the compound represented by formula I or its medicinal salt, -X- is selected from -O-, -N-, -S-, and -SO2-.
[0009] In some embodiments, in the compound represented by formula I or a medicinal salt thereof, W is a nitrogen atom.
[0010] In some embodiments, in the compound represented by formula I or a medicinal salt thereof, W is a carbon atom.
[0011] In some embodiments, in the compound represented by formula I or a medicinal salt thereof, ring A is selected from a 5-6 membered heteroaryl group. R5 is C 1-6 Alkyl alkyl group, C 1-6 Selected from an alkoxy group and a methylenecyclopropyl group, the above C 1-6 Alkyl alkyl group, C 1-6 The alkoxy group and methylenecyclopropyl group are optionally substituted with one or more substituents selected from halogen, hydroxyl, cyano, and nitro groups.
[0012] In some embodiments, in the compound represented by formula I or a medicinal salt thereof, R5 is C 1-6 Selected from alkyl groups, the above C 1-6 The alkyl group is optionally substituted with one or more halogens.
[0013] In some embodiments, in the compound represented by formula I or its medicinal salt, R5 is selected from a methyl group, and the methyl group is optionally substituted with 1 to 3 halogens.
[0014] In some embodiments, in the compound represented by formula I or its medicinal salt, ring A is selected from a 5-6 membered heteroaryl group, and R5 is selected from a halogen, a nitro group, or a cyano group.
[0015] In a second aspect, the present disclosure provides compounds represented by formulas Ia to Il or pharmaceutically active salts thereof. [ka] R1, R2, R5, Y, ring B, and R3 are defined as in equation I.
[0016] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R1 is hydrogen, C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 Selected from alkoxy groups, halogens, cyano groups, nitro groups, and hydroxyl groups, the above C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 The alkoxy group can be one or more R groups of any choice. 4a It will be replaced with.
[0017] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R1 is selected from hydrogen, a 3-6 membered heterocyclyl group, a 5-6 membered heteroaryl group, an -O-3-6 membered heterocyclyl group, or an -O-5-6 membered heteroaryl group, and the above 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group may be optionally one or more R1s. 4a It will be replaced with.
[0018] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R1 is hydrogen, C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 Selected from alkoxy groups, the above C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 The alkoxy group can be one or more R groups of any choice. 4a It will be replaced with.
[0019] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R1 is selected from hydrogen, a methyl group, a trifluoromethyl group, or a halogen.
[0020] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or in medicinal salts thereof, R1 is selected from hydrogen.
[0021] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R2 is hydrogen, C 1-6 Alkyl alkyl group, C 1-6 Selected from alkoxy groups, hydroxyl groups, halogens, nitro groups, cyano groups, amino groups, carboxyl groups, and 3-6 membered cycloalkyl groups, the above C 1-6 Alkyl alkyl group, C 1-6 The alkoxy group and the 3-6 membered cycloalkyl group can be optionally one to multiple R groups. 4b It will be replaced with.
[0022] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R2 is selected from hydrogen, a 3-6 membered heterocyclyl group, a 5-6 membered heteroaryl group, an -O-3-6 membered heterocyclyl group, or an -O-5-6 membered heteroaryl group, and the above 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group can be optionally selected from one to more R2s. 4b It will be replaced with.
[0023] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R2 is hydrogen, C 1-6 Selected from alkyl groups and halogens, the above C 1-6 Alkyl alkyl groups can be one or more R as optional. 4b It will be replaced with.
[0024] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or their medicinal salts, R2 is C 1-6 Selected from alkyl groups, the above C 1-6 Alkyl alkyl groups can be one or more R as optional. 4b It will be replaced with.
[0025] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or pharmaceutically acceptable salts thereof, R2 is selected from hydrogen, a hydroxyl group, a halogen, a nitro group, a cyano group, or an amino group.
[0026] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, or Il, or in medicinal salts thereof, R2 is selected from a methyl group.
[0027] In a third aspect, the Disclosure further provides compounds represented by formulas I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically usable salts thereof: [ka] R1, R2, R5, Y, ring B, and R3 are defined as in equation I.
[0028] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, Y is an oxygen atom.
[0029] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, Y is a nitrogen atom.
[0030] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, ring B is [ka] Selected from, the above [ka] C is optional. 1-6 Alkyl alkyl group, C 1-6 Substituted with 1 to 3 substituents selected from alkoxy groups, methylenecyclopropyl groups, halogens, nitro groups, and cyano groups, the above C 1-6 Alkyl alkyl group, C 1-6 The alkoxy group and methylenecyclopropyl group are optionally substituted with one or more substituents selected from halogen, hydroxyl, cyano, and nitro groups.
[0031] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, ring B is [ka] Selected from, the above [ka] C is optional. 1-6 Alkyl alkyl group, C 1-6 Substituted with 1 to 3 substituents selected from alkoxy groups, methylenecyclopropyl groups, halogens, nitro groups, and cyano groups, the above C 1-6 Alkyl alkyl group, C 1-6 The alkoxy group and methylenecyclopropyl group are optionally substituted with one or more substituents selected from halogen, hydroxyl, cyano, and nitro groups.
[0032] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, ring B is [ka] Selected from, the above [ka] C is optional. 1-6 Substituted with 1 to 3 substituents selected from alkyl groups, halogens, and cyano groups, the above C 1-6 The alkyl group is optionally substituted with one or more substituents selected from halogens, hydroxyl groups, cyano groups, and nitro groups.
[0033] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, ring B is [ka] Selected from among them, R3 is ligated to the * end.
[0034] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, ring B is [ka] Selected from among them, R3 is ligated to the * end.
[0035] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, ring B is [ka] Selected from among them, R3 is ligated to the * end.
[0036] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, ring B is [ka] Selected from, R3 is ligated to the *terminus, as above [ka] C is optional. 1-6 Substituted with 1 to 3 substituents selected from alkyl groups, halogens, and cyano groups, the above C 1-6The alkyl group is optionally substituted with one or more substituents selected from halogens, hydroxyl groups, cyano groups, and nitro groups.
[0037] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, R3 is hydrogen, C 1-6 Alkyl alkyl group, C 1-6 Selected from alkoxy groups, 3-6 membered cycloalkyl groups, 3-6 membered heterocyclyl groups, 5-6 membered heteroaryl groups, -O-3-6 membered heterocyclyl groups, and -O-5-6 membered heteroaryl groups, the above C 1-6 Alkyl alkyl group, C 1-6 The alkoxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group can be optionally one to multiple R groups. 4c It will be replaced with.
[0038] In some embodiments, in compounds represented by formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, R3 is selected from hydrogen, a hydroxyl group, a halogen, a nitro group, a cyano group, an amino group, or a carboxyl group.
[0039] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, R3 is hydrogen, C 1-6 Alkyl alkyl group, C 1-6selected from an alkoxy group and a 3- to 6-membered cycloalkyl group, the above-mentioned C 1-6 alkyl group, C 1-6 alkoxy group, and 3- to 6-membered cycloalkyl group are optionally substituted with one or more R 4c .
[0040] In some embodiments, in the compound represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-l, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or a pharmaceutically acceptable salt thereof, R3 is selected from a methyl group, a methoxy group, an ethyl group, a propyl group, an ethoxy group, a cyclopropoxy group, a cyclobutyl group, and a cyclobutoxy group, and the above-mentioned methyl group, methoxy group, ethyl group, propyl group, ethoxy group, cyclopropoxy group, cyclobutyl group, and cyclobutoxy group are optionally substituted with 1 to 3 R 4c .
[0041] In some embodiments, in the compound represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-l, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or a pharmaceutically acceptable salt thereof, R3 is selected from a methyl group, an ethyl group, a propyl group, and a cyclobutyl group, and the above-mentioned methyl group, ethyl group, propyl group, and cyclobutyl group are optionally substituted with 1 to 3 R 4c .
[0042] In some embodiments, in the compound represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-l, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or a pharmaceutically acceptable salt thereof, R3 is C 1-6 selected from alkyl groups, the above-mentioned C 1-6 alkyl group is substituted with one or more R 4c .
[0043] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, R3 is selected from methyl groups, and the methyl groups are one to multiple R 4c It will be replaced with.
[0044] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or pharmaceutically acceptable salts thereof, R3 is a trifluoromethyl group, an ethyl group, an isopropyl group, a difluoroethoxy group, an ethoxy group, a cyclopropoxy group, a cyclobutyl group, -CH2OCH3, [ka] They are selected from among them.
[0045] In some embodiments, in compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or pharmaceutically acceptable salts thereof, R3 is a trifluoromethyl group, a difluoromethyl group, an ethyl group, a cyclopropyl group, -CH2OCH3, -CH2OCHF2, -CH2OCH2CH3, [ka] They are selected from among them.
[0046] In some embodiments, in the compound represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-l, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or a pharmaceutically acceptable salt thereof, R5 is C 1-6 selected from alkyl groups, and the above C 1-6 alkyl group is optionally substituted with one or more halogens.
[0047] In some embodiments, in the compound represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-l, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or a pharmaceutically acceptable salt thereof, R5 is selected from methyl groups, and the methyl group is optionally substituted with 1 to 3 halogens.
[0048] In some embodiments, in the compound represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-l, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or a pharmaceutically acceptable salt thereof, R 4a are each independently selected from halogen, hydroxy group, oxo, nitro group, cyano group, and amino group.
[0049] In some embodiments, in the compound represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-l, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k or I'-l, or a pharmaceutically acceptable salt thereof, R 4a are each independently C 1-6 alkyl group, C 1-6 selected from alkoxy groups, 3- to 6-membered cycloalkyl groups, 3- to 6-membered heterocyclyl groups, and 3- to 6-membered heterocycloalkoxy groups.
[0050] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4a Each of them is independently C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 3-6 membered heterocycloalkoxy group, C 3-8 Selected from a cycloalkenyloxy group, a 5-6 membered aryl group, or a 3-6 membered heteroaryl group.
[0051] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4a These are independently selected from halogen, methyl, ethyl, methoxy, ethoxy, cyclopropoxy, and cyclobutoxy groups.
[0052] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4b Each of these is independently selected from halogen, hydroxyl, oxo, nitro, cyano, and amino groups.
[0053] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4b Each of them is independently C 1-6 Alkyl alkyl group, C 1-6 Selected from alkoxy groups, 3-6 membered cycloalkyl groups, 3-6 membered heterocyclyl groups, and 3-6 membered heterocycloalkoxy groups.
[0054] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4b Each of them is independently C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 3-6 membered heterocycloalkoxy group, C 3-8 Selected from a cycloalkenyloxy group, a 5-6 membered aryl group, or a 3-6 membered heteroaryl group.
[0055] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4b Each of these is independently selected from halogen, methyl, ethyl, methoxy, ethoxy, cyclopropoxy, and cyclobutoxy groups.
[0056] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4c Each of these is independently selected from halogen, hydroxyl, oxo, nitro, cyano, and amino groups.
[0057] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4c Each of them is independently C 1-6 Alkyl, halo C 1-6 Alkyl alkyl group, C 1-6 Alkoxy group, Halo C 1-6 Selected from alkoxy groups, 3-6 membered cycloalkyl groups, 3-6 membered heterocyclyl groups, and 3-6 membered heterocycloalkoxy groups.
[0058] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4c Each of them is independently C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 3-6 membered heterocycloalkoxy group, C 3-8 Selected from a cycloalkenyloxy group, a 5-6 membered aryl group, or a 3-6 membered heteroaryl group.
[0059] In some embodiments, compounds represented by formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, I'-a, I'-b, I'-c, I'-d, I'-e, I'-f, I'-g, I'-h, I'-i, I'-j, I'-k, or I'-l, or their pharmaceutically acceptable salts, R 4c Each of these is independently selected from halogen, methyl, ethyl, methoxy, ethoxy, cyclopropoxy, and cyclobutoxy groups.
[0060] In a fourth aspect, the disclosure further provides compounds or medicinal salts thereof such as: [ka] [ka] [ka] [ka] [ka] [ka] [ka] .
[0061] In a fifth aspect, the disclosure further provides compounds or medicinal salts thereof such as: [ka] [ka] [ka] .
[0062] In a sixth aspect, the disclosure further provides isotopic substitutions of the compounds shown in the first, second, third, fourth, or fifth aspect, preferably the isotopic substitution being a deuterium atom substitution.
[0063] In a seventh aspect, the Disclosure provides a pharmaceutical composition comprising a compound shown in the first, second, third, fourth, or fifth aspect, or a pharmaceutically acceptable salt thereof, or an isotopic substitution described in the sixth aspect, and a pharmaceutically acceptable excipient.
[0064] In some embodiments, the unit dose of the above pharmaceutical composition is 0.001 to 1000 mg.
[0065] In one embodiment, based on the total weight of the composition, the pharmaceutical composition contains 0.01% to 99.99% of the compound or a medicinal salt thereof. In another embodiment, the pharmaceutical composition contains 0.1% to 99.9% of the compound or a medicinal salt thereof. In yet another embodiment, the pharmaceutical composition contains 0.5% to 99.5% of the compound or a medicinal salt thereof. In yet another embodiment, the pharmaceutical composition contains 1% to 99% of the compound or a medicinal salt thereof. In yet another embodiment, the pharmaceutical composition contains 2% to 98% of the compound or a medicinal salt thereof.
[0066] In one embodiment, based on the total weight of the composition, the pharmaceutical composition contains 0.01% to 99.99% of pharmaceutically acceptable excipients. In another embodiment, the pharmaceutical composition contains 0.1% to 99.9% of pharmaceutically acceptable excipients. In yet another embodiment, the pharmaceutical composition contains 0.5% to 99.5% of pharmaceutically acceptable excipients. In yet another embodiment, the pharmaceutical composition contains 1% to 99% of pharmaceutically acceptable excipients. In yet another embodiment, the pharmaceutical composition contains 2% to 98% of pharmaceutically acceptable excipients.
[0067] This disclosure further provides a method for preventing and / or treating patients with LPA1-related conditions, comprising administering to such patients a therapeutically effective amount of a compound shown in the first, second, third, fourth, or fifth embodiment or a pharmaceutically usable salt thereof, or an isotope substitution as described in the sixth embodiment, or a pharmaceutical composition as described in the seventh embodiment.
[0068] This disclosure further provides a method for preventing and / or treating patients with organ fibrosis, respiratory diseases, kidney diseases, liver diseases, inflammatory diseases, neurological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, pain, urinary tract diseases, eye diseases, metabolic diseases, cancer, and transplant organ rejection, comprising administering to such patients a therapeutically effective amount of a compound shown in the first, second, third, fourth, or fifth embodiment or a medicinal salt thereof, or an isotope substitution described in the sixth embodiment, or a pharmaceutical composition described in the seventh embodiment.
[0069] This disclosure further provides the use of compounds shown in the first, second, third, fourth, or fifth embodiment or their medicinal salts, or isotopic substitutions as described in the sixth embodiment, or pharmaceutical compositions as described in the seventh embodiment, in the preparation of agents for preventing and / or treating conditions associated with LPA1.
[0070] This disclosure further provides the use of compounds shown in the first, second, third, fourth, and fifth embodiments or their medicinal salts, or isotope substitutions as described in the sixth embodiment, or pharmaceutical compositions as described in the seventh embodiment, in the preparation of agents for preventing and / or treating organ fibrosis, respiratory diseases, kidney diseases, liver diseases, inflammatory diseases, neurological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, pain, urinary tract diseases, eye diseases, metabolic diseases, cancer, and transplant organ rejection.
[0071] This disclosure further provides uses for compounds shown in the first, second, third, fourth, or fifth embodiment, or pharmaceutically usable salts thereof, or isotope substitutions as described in the sixth embodiment, or pharmaceutical compositions as described in the seventh embodiment, used in agents for preventing and / or treating conditions related to LPA1.
[0072] This disclosure further provides uses for compounds shown in the first, second, third, fourth, or fifth embodiment, or pharmaceutically active salts thereof, or isotope substitutions as described in the sixth embodiment, or pharmaceutical compositions as described in the seventh embodiment, used in agents for preventing and / or treating organ fibrosis, respiratory diseases, kidney diseases, liver diseases, inflammatory diseases, neurological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, pain, urinary tract diseases, eye diseases, metabolic diseases, cancer, and transplant organ rejection.
[0073] The organ fibrosis degenerative diseases listed above include, but are not limited to, pulmonary fibrosis (especially idiopathic pulmonary fibrosis), renal fibrosis, hepatic fibrosis, cutaneous fibrosis, intestinal fibrosis, and ocular fibrosis.
[0074] The respiratory diseases mentioned above include, but are not limited to, asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, cough, chronic cough, and respiratory failure.
[0075] The above-mentioned kidney diseases include, but are not limited to, acute kidney injury and chronic kidney disease.
[0076] The liver diseases mentioned above include, but are not limited to, alcoholic steatohepatitis, non-alcoholic steatohepatitis, acute chronic hepatitis, cirrhosis, and impaired liver function.
[0077] The inflammatory diseases mentioned above include, but are not limited to, autoimmune diseases, inflammation, arthritis, rheumatoid arthritis, scleroderma, Raynaud's phenomenon, and chronic pruritus.
[0078] The neurological disorders mentioned above include, but are not limited to, Alzheimer's disease, Parkinson's disease, neurodegeneration, traumatic brain injury, epilepsy, mental illness, and sleep disorders.
[0079] The cardiovascular and cerebrovascular diseases mentioned above include, but are not limited to, collagen vascular disease, myocardial infarction, stroke, thrombosis, atherosclerosis, heart failure, and hypertension.
[0080] The gastrointestinal disorders mentioned above include, but are not limited to, colon syndrome, inflammatory bowel disease, gastrointestinal disorders, and gastrointestinal dysfunction.
[0081] The pains mentioned above include, but are not limited to, cancer pain, neuropathic pain, inflammatory pain, surgical pain, visceral pain, toothache, premenstrual pain, central pain, burn pain, migraine, or cluster headache, and chronic pain.
[0082] The above-mentioned urinary tract disorders include urinary incontinence, voiding dysfunction, cystitis, benign prostatic hyperplasia, voiding dysfunction associated with benign prostatic hyperplasia, bladder neck sclerosis, and underactive bladder.
[0083] The above-mentioned eye diseases include macular degeneration and diabetic retinopathy.
[0084] The cancers listed above include, but are not limited to, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, intestinal cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, and tumor metastases.
[0085] The medicinal salts of the compounds described in this disclosure may be selected from inorganic salts or organic salts.
[0086] The compounds relating to this disclosure may be in the form of specific geometric or stereoisomers. This disclosure is intended to encompass all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and their racemic mixtures and other mixtures, such as mixtures rich in enantiomers or diastereomers. Substituents such as alkyl groups may have other chiral carbon atoms. All such isomers and mixtures thereof are included in the scope of this disclosure. Compounds containing chiral carbon atoms relating to this disclosure can be isolated in the form of optically active pures or racemic forms. The optically active pures may be separated from racemic mixtures or synthesized using chiral starting materials or chiral reagents.
[0087] Optically active (R)- and (S)- isomers and D- and L isomers can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. To obtain one enantiomer of a compound in this disclosure, it can be prepared by asymmetric synthesis or induction with a chiral aid, from which the resulting diastereomer mixture can be isolated and the group splitting assisted to provide the required pure enantiomer. Alternatively, if the molecule contains a basic functional group (e.g., an amino group) or an acidic functional group (e.g., a carboxyl group), a salt of the diastereomer can be formed with a suitable optically active acid or base, and the diastereomer can be split by conventional methods well known in the art, after which it can be recovered to obtain the pure enantiomer. The isolation of enantiomers and diastereomers is generally completed by chromatography, which employs a chiral stationary phase and is optionally combined with a chemical induction method (e.g., producing a carbamate salt from an amine).
[0088] In the chemical structure of the compound described in the present invention, [ka] This type of bond indicates that the arrangement is not specified, meaning that if chiral isomers exist in the chemical structure, [ka] The combination is [ka] It may be so, or [ka] It includes both of the following configurations simultaneously. In the chemical structure of the compounds described herein, [ka] This type of combination does not specify a placement, that is, [ka] The configuration of this combination may be an E configuration or a Z configuration, or it may include both E and Z configurations simultaneously.
[0089] The compounds and intermediates relating to this disclosure may exist in different tautomerized forms, and all such forms are included within the scope of this disclosure. The terms “tautomer” or “tautomerized form” refer to structural isomers of different energies that can be interconverted over a low energy barrier. For example, proton tautomers (also called proton transfer tautomers) include interconversions by protricsis, such as keto-enols and imine-enamines, and lactam-lactim isomerization. An example of lactam-lactim equilibrium is between A and B as follows: [ka]
[0090] All compounds in this invention can be described as type A or type B. All tautomers are within the scope of this invention. The naming of the compounds does not exclude any tautomer.
[0091] This disclosure is the same as described herein, but further includes several isotopically labeled compounds in which one or more atoms are substituted with atoms having atomic weights or mass numbers different from those commonly found in nature. Examples of isotopes that can be bound to the compounds of this disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, for example, respectively 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Examples include Cl.
[0092] Unless otherwise specified, where one position is specifically designated as deuterium (D), that position should be understood to be deuterium having an abundance at least 1000 times higher than the natural abundance of deuterium (0.015%) (i.e., at least 10% deuterium incorporated). Having an abundance higher than the natural abundance of deuterium in the example compounds may mean deuterium with an abundance of at least 1000 times, at least 2000 times, at least 3000 times, at least 4000 times, at least 5000 times, at least 6000 times, or even greater. This disclosure further includes compounds in various deuterated forms. Each available hydrogen atom bonded to a carbon atom may be independently substituted with a deuterium atom. Those skilled in the art can synthesize compounds in deuterated forms by referring to relevant literature. When preparing compounds in their deuterated form, commercially available deuterated starting materials may be used, or they may be synthesized using deuterated reagents by conventional techniques. Deuterated reagents include, but are not limited to, borane deuterated, borane trihydrofuran solution, lithium aluminum hydride deuterated, iodoethane deuterated, and iodomethane deuterated.
[0093] "Optionally" or "optionally" means that the event or situation described thereafter may or may not occur, and this description includes both cases in which the event or situation occurs and cases in which it does not. For example, "Citr selectively substituted with a halogen or cyano group" 1-6 The term "alkyl group" means that a halogen or cyano group may or may not be present, and this explanation includes cases where the alkyl group is substituted with a halogen or cyano group, and cases where the alkyl group is not substituted with a halogen or cyano group.
[0094] Explanation of terms: "Pharmaceutical composition" means a mixture of one or more compounds described herein or physiologically medicinal salts or prodrugs thereof with other chemical components, and other components such as physiologically medicinal vectors and excipients. The pharmaceutical composition is intended to facilitate administration to a living organism and contribute to the absorption of the active ingredient, thereby exerting further biological activity.
[0095] "Medicinal excipients" include, but are not limited to, any auxiliaries, vectors, excipients, flow enhancers, sweeteners, diluents, preservatives, dyes / colorants, flavorings, surfactants, humectants, dispersants, suspending agents, stabilizers, isotonic agents, solvents, or emulsifiers approved by the U.S. Food and Drug Administration for use in humans or livestock.
[0096] As described in this disclosure, “effective dose” or “effective therapeutic dose” includes an amount sufficient to improve or prevent the symptoms or condition of a medical condition. The effective dose further means an amount sufficient to allow or facilitate a diagnosis. The effective dose used for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient’s overall health, the method, route and dosage of administration, and the severity of side effects. The effective dose may also be the maximum dose or administration plan that avoids significant side effects or toxic effects.
[0097] The term "alkyl group" refers to saturated aliphatic hydrocarbon groups containing 1 to 20 carbon atoms in a linear or branched chain. These are alkyl groups containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, and their various branched isomers. Alkyl groups may be substituted or unsubstituted, and if substituted, the substituent may be substituted at any available bond point, preferably independently of a halogen, hydroxyl, oxo, cyano, amino, or C 1-6 Alkyl alkyl group, C 1-6The group is one or more groups selected from an alkoxy group, a 3- to 7-membered cycloalkyl group, or a 3- to 7-membered heterocycloalkyl group, and the alkyl group, alkoxy group, cycloalkyl group, or heterocycloalkyl group may be optionally substituted with a halogen, hydroxyl group, nitro group, cyano group, or amino group.
[0098] The term "cycloalkyl group" refers to saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituents, where the cycloalkyl group contains 3 to 20 carbon atoms, preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, and cyclohexadienyl groups, while polycyclic cycloalkyl groups include cycloalkyl groups of spiro rings, fused rings, and crosslinked rings. Cycloalkyl groups may be substituted or unsubstituted, and if substituted, the substituents may be substituted at any available bond point, preferably independently of halogens, hydroxyl groups, oxo, cyano, amino, and C 1-6 Alkyl alkyl group, C 1-6 The alkyl group is substituted with one or more groups selected from an alkoxy group, a 3- to 7-membered cycloalkyl group, or a 3- to 7-membered heterocycloalkyl group, and the alkyl group, alkoxy group, cycloalkyl group, or heterocycloalkyl group may be optionally substituted with a halogen, a hydroxyl group, a nitro group, a cyano group, or an amino group.
[0099] The term "heterocyclyl group" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, of which one or more ring atoms are nitrogen, oxygen, or S(O). m The heteroatoms are selected from (where m is an integer from 0 to 2), but do not contain the -OO-, -OS-, or -SS- ring portions, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms, and more preferably 3 to 6 ring atoms. Non-limiting examples of "heterocyclyl groups" are: [ka] This includes, among others.
[0100] The above heterocyclyl ring may be condensed with an aryl group or a heteroaryl group, of which the ring linked to the parent structure is a heterocycloalkyl group, and non-limiting examples thereof are: [ka] This includes, among others.
[0101] The heterocyclyl group may be optionally substituted or left unsubstituted. If substituted, the substituents can independently be halogen, hydroxyl, oxo, cyano, amino, or C. 1-6 Alkyl alkyl group, C 1-6 Preferably, one or more groups selected from an alkoxy group, a 3-6 membered cycloalkyl group, or a 3-6 membered heterocycloalkyl group are used, and the alkyl group, alkoxy group, cycloalkyl group, or heterocycloalkyl group may be optionally substituted with a halogen, hydroxyl group, nitro group, cyano group, or amino group.
[0102] The term "alkoxy group" refers to an -O-(alkyl group), and the definition of an alkyl group is as described above. Non-exclusive examples of alkoxy groups include methoxy, ethoxy, propoxy, and butoxy groups. Alkoxy groups may be optionally substituted or left unsubstituted. If substituted, the substituents can independently be halogens, hydroxyl groups, oxo, cyano, amino, or C. 1-6 Alkyl alkyl group, C 1-6 Preferably, one or more groups selected from an alkoxy group, a 3- to 7-membered cycloalkyl group, or a 3- to 7-membered heterocycloalkyl group are used, and the alkyl group, alkoxy group, cycloalkyl group, or heterocycloalkyl group may be optionally substituted with a halogen, hydroxyl group, nitro group, cyano group, or amino group.
[0103] A "monovalent group" is an atom or group obtained by "formally" removing one monovalent atom from a compound. A "subunit" is an atom or group of atoms obtained by "formally" removing two monovalent or one divalent atom from a compound. An "alkylene group" represents the portion remaining after removing two hydrogen atoms from an alkane molecule and includes linear and branched subunits of 1 to 20 carbon atoms. Non-limiting examples of alkylene groups containing 1 to 6 carbon atoms are the methylene group (-CH2-) and the ethylidene group (e.g., -CH2CH2- or -CH(CH3)-). Unless otherwise specified, alkylene groups may be substituted or unsubstituted, and if substituted, the substituents may be substituted at any available bond point, preferably independently a halogen, a hydroxyl group, a cyano group, an amino group, or C 1-6 Alkyl alkyl group or C 1-6 It is one or more groups selected from alkoxy groups.
[0104] Similarly, the definitions of "alkylene oxy group," "alkenylene group," "alkenylene oxy group," "cycloalkylene group," and "heterocyclylene group" are the same as those for "alkylene group."
[0105] The term "aryl group" refers to a 6-14 member all-carbon monocyclic or condensed polycyclic (i.e., a ring sharing adjacent carbon atom pairs) group having a conjugated π-electron system, preferably 6-12 membered, such as the phenyl group and the naphthyl group. The above aryl group ring may be condensed with a heteroaryl group, a heterocycloalkyl group, or a cycloalkyl group, in which the ring linked to the parent structure is the aryl group ring, and non-limiting examples include: [ka] Includes, The aryl group may or may not be substituted. If substituted, the substituents can independently be halogen, hydroxyl, oxo, nitro, cyano, or C. 1-6 Alkyl alkyl group, C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C3-6 Cycloalkoxy group, 3-6 membered heterocycloalkoxy group, C 3-8 Preferably, one or more groups selected from a cycloalkenyloxy group, a 5-6 membered aryl group, or a heteroaryl group, and the above C 1-6 Alkyl alkyl group, C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, C 3-6 Cycloalkoxy group, 3-6 membered heterocycloalkoxy group, C 3-8 The cycloalkenyloxy group, 5-6 membered aryl group, or heteroaryl group can be optionally a halogen, hydroxyl group, cyano group, amino group, or C 1-6 Alkyl alkyl group or C 1-6 It is substituted with one or more substituents selected from alkoxy groups.
[0106] The term "heteroaryl group" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, of which the heteroatoms are selected from oxygen, sulfur, and nitrogen. Heteroaryl groups are preferably 6 to 12 members, and more preferably 5 or 6 members. For example, non-limiting examples include imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazolyl, pyrazinyl, triazolyl, indazolyl, and benzimidazolyl groups. [ka] This includes, among others.
[0107] The above heteroaryl ring may be condensed with an aryl group, a heterocycloalkyl group, or a cycloalkyl ring, of which the ring linked to the parent structure is a heteroaryl ring, and non-limiting examples thereof are: [ka] Includes.
[0108] The heteroaryl group may be optionally substituted or left unsubstituted. If substituted, the substituents can independently be halogen, hydroxyl, cyano, amino, or C. 1-6 Alkyl alkyl group or C 1-6 One or more groups selected from alkoxy groups are preferred.
[0109] The term "spiro ring" refers to a compound in which two rings share one atom. Non-exclusive examples of spirocycloalkyl groups include: [ka] Includes.
[0110] The term "condensed ring" refers to a compound formed by the condensation of two or more rings sharing two adjacent atoms. Non-exclusive examples of condensed cycloalkyl groups include: [ka] Includes.
[0111] The term "crosslinked ring" refers to a structure formed by two or more cyclic structures sharing two non-adjacent ring atoms. Crosslinked cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic depending on the number of rings they comprise, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of crosslinked cycloalkyl groups include: [ka]
[0112] The term "hydroxyl group" refers to the -OH group.
[0113] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0114] The term "cyano group" refers to -CN.
[0115] The term "amino group" refers to -NH2.
[0116] The term "nitro group" refers to -NO2.
[0117] The term "oxo" refers to an =O substituent.
[0118] The term "carboxyl group" refers to the COOH group.
[0119] "Substitution" means that one or more hydrogen atoms in a group, preferably five or fewer, more preferably one to three hydrogen atoms, are substituted by a number of substituents that correspond to each other independently. If the substituent is a ketone or oxo (i.e., =O), two (two) hydrogen atoms on the atom are substituted. [Modes for carrying out the invention]
[0120] The present disclosure will be further described below in conjunction with examples, but these examples are not intended to limit the scope of the present disclosure.
[0121] Experimental methods in the examples of this disclosure that do not specify concrete conditions generally follow conventional conditions or conditions recommended by the raw material or product manufacturers. Reagents whose specific source is not specified are commercially available, standard reagents.
[0122] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (LCMS). The NMR shift (δ) was 10 -6 The values are expressed in units of ppm. A Bruker AVANCE-400 nuclear magnetic resonance spectrometer was used for the NMR measurements, and the measurement solvents were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), with tetramethylsilane (TMS) as the internal standard. The stereochemistry of the optical isomers (isomers) of the compound can be further confirmed by measuring the single crystal parameters.
[0123] For high performance liquid chromatography (HPLC) measurements, Waters ACQUITY ultra high performance LC, Shimadzu LC-20A systems, Shimadzu LC-2010HT series or Agilent 1200 LC high pressure liquid chromatograph (ACQUITY UPLC BEH C18 1.7 μm 2.1×50 mm column, Ultimate XB-C18 3.0×150 mm column or Xtimate C18 2.1×30 mm column) were used.
[0124] For mass spectrometry (MS) measurements, the Waters SQD2 mass spectrometer was used, scanning in positive / negative ion mode with a mass scanning range of 100 to 1200.
[0125] For chiral HPLC analytical measurements, Chiralpak IG-3 100×4.6 mm I.D., 3 μm, Chiralpak AD-3 150×4.6 mm I.D., 3 μm, Chiralpak IH-3 50×4.6 mm I.D., 3 μm, Chiralpak AS-3 150×4.6 mm I.D., 3 μm, Chiralpak AS-3 100×4.6 mm I.D., 3 μm, Chiralcel OJ-3 100×4.6 mm I.D., 3 μm columns were used.
[0126] As the silica gel plate for thin layer chromatography, Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates were used. The specification of the silica gel plate used for thin layer chromatography (TLC) was 0.15 to 0.2 mm, and the specification for separation and purification of products by thin layer chromatography was 0.4 to 0.5 mm.
[0127] As the flash column chromatography system, Combiflash Rf150 (TELEDYNE ISCO) or Isolara one (Biotage) was used.
[0128] For normal-phase column chromatography, Yantai Huanghai silica gel of 100-200 mesh, 200-300 mesh or 300-400 mesh is generally used as the carrier, or Changzhou Santai pre-packed ultra-high purity normal-phase silica gel columns (40-63 μm, 60, 12 g, 25 g, 40 g, 80 g or other specifications) are used.
[0129] For reversed-phase column chromatography, Changzhou Santai pre-packed ultra-high purity C18 silica gel columns (20-45 μm, 100 Å, 40 g, 80 g, 120 g, 220 g or other specifications) are generally used.
[0130] For the high-pressure column purification system, Waters AutoP is used, and the Waters XBridge BEH C18 OBD Prep Column (130 Å, 5 μm, 19×150 mm) or Atlantis T3 OBD Prep Column (100 Å, 5 μm, 19×150 mm) is used in matching therewith.
[0131] As the chiral preparative column, DAICEL CHIRALPAK AS (250 mm×30 mm, 10 μm), DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm), DAICEL CHIRALCEL OJ (250 mm×30 mm, 10 μm), DAICEL CHIRALPAK IG (250 mm×30 mm, 10 μm) or Waters SFC150AP ChiralPak IH (250 mm×30 mm, 10 μm) is used.
[0132] The known starting materials in the present disclosure may be synthesized by or according to methods known in the art, or may be purchased from companies such as Shanghai Titan Technology, ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, and Darey Chemicals.
[0133] Unless otherwise specified in the examples, all reactions can be carried out under a nitrogen atmosphere.
[0134] An argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen balloon with a volume of approximately 1 L.
[0135] A hydrogen atmosphere refers to a reaction flask connected to a hydrogen balloon with a volume of approximately 1 L.
[0136] For the pressurized hydrogenation reaction, a Parr 3916EKX type hydrogenator and either a QL-500 type hydrogen generator or an HC2-SS type hydrogenator were used.
[0137] The hydrogenation reaction typically involved repeating the process of evacuating and filling with hydrogen three times.
[0138] A CEM Discover-S 908860 microwave reactor was used for the microwave reaction.
[0139] In the examples, unless otherwise specified, "solution" refers to an aqueous solution.
[0140] In the examples, unless otherwise specified, the reaction temperature was room temperature, ranging from 20 to 30°C.
[0141] Thin-layer chromatography (TLC) was used to monitor the reaction process in the examples.
[0142] Example 1 5-((2-methyl-6-(1-methyl-5-(((4-(trifluoromethyl)pyrimidine-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid(1) [ka] [ka]
[0143] Step 1: 5-Hydroxyhexahydrocyclopentadiene-2(1H)-one(1b) The starting material, cis-tetrahydrocyclopentadiene-2,5(1H,3H)-dione 1a (24 g, 173.7 mmol), was dissolved in ethanol (500 mL), cooled to 0°C, and sodium borohydride (1.47 g, 43.4 mmol) was added. The reaction was carried out at 0°C for 2 hours with stirring. The reaction mixture was quenched with acetic acid (10 mL), concentrated, and the residue was purified by silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 1b (9 g, yield 37.0%). 1 H NMR: (400 MHz, CDCl3) δ 4.55 - 4.37 (m, 1H), 2.90 - 2.75 (m, 2H), 2.64 - 2.48 (m, 2H), 2.36 - 2.14 (m, 4H), 1.65 - 1.49 (m, 3H).
[0144] Step 2: 5-((tert-butyldiphenyldiphenyl)oxy)hexahydrocyclopentadiene-2(1H)-one(1c) 1b (15 g, 107.0 mmol) was dissolved in dichloromethane (150 mL), imidazole (21.8 g, 321.0 mmol) was added, and the mixed solution was cooled to 0°C. Then tert-butyldiphenylchlorosilane (30.5 mL, 117.7 mmol) was added, and the reaction was carried out at 0°C for 1 hour with stirring. The reaction solution was washed with 1 M hydrochloric acid solution (150 mL x 3), washed with saturated saline solution (300 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 1c (41 g, crude product), which was used directly in the next reaction without further purification.
[0145] Step 3: Methyl 5-((tert-butyldiphenylsilyl)oxy)-2-oxooctahydrocyclopentadiene-1-carboxylate (1d) A solution of 1c (41 g, 108.3 mmol) in tetrahydrofuran (500 mL) was cooled to 0°C, 60% sodium hydride (17.3 g, 433.2 mmol) was added, then dimethyl carbonate (19.5 g, 216.6 mmol) was added, the mixture was heated to 60°C and reacted under stirring for 3 hours. Water (150 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (100 mL × 3), the combined organic phases were washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to afford the title product 1d (25 g, yield 52.9%). MS (ESI): m / z = 459.1 [M+Na] + .
[0146] Step 4: Methyl 5-((tert-butyldiphenylsilyl)oxy)-2-hydroxyoctahydrocyclopentadiene-1-carboxylate (1e) 1d (32 g, 73.3 mmol) was dissolved in tetrahydrofuran (350 mL), cooled to 0°C, sodium borohydride (2.48 g, 73.3 mmol) was added, and the mixture was reacted under stirring at 0°C for 3 hours. The reaction was quenched with 0.5 M hydrochloric acid solution (30 mL), extracted with ethyl acetate (30 mL × 3), the combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to afford the title product 1e (9 g, yield 28.0%). MS (ESI): m / z = 461.2 [M+Na] + .
[0147] Step 5: Methyl 5-((tert-butyldiphenylsilyl)oxy)-2-((methylsulfonyl)oxy)octahydrocyclopentadiene-1-carboxylate (1f) 1e (9 g, 20.5 mmol) was dissolved in dichloromethane (20 mL), triethylamine (5.19 g, 51.3 mmol) was added, the mixture was cooled to 0°C, and methanesulfonic anhydride (5.36 g, 30.8 mmol) was added. The reaction mixture was then returned to room temperature and allowed to react with stirring for 3 hours. The reaction mixture was washed with water (25 mL x 2), then with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 1f (9 g, yield 84.9%). MS (ESI): m / z = 539.1 [M+Na] + .
[0148] Step 6: 5-((tert-butyldiphenyldiphenyl)oxy)-3,3a,4,5,6,6a-hexahydrocyclopentadiene-1-carboxylate methyl (1g) 1f (9 g, 17.4 mmol) was dissolved in toluene (100 mL), and 1,8-diazabicyclo[5.4.0]undeca-7-ene (5.3 g, 34.8 mmol) was added. The mixture was heated to 90°C and reacted with stirring for 2 hours. The reaction mixture was concentrated, and the residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain 1 g (6.5 g, yield 88.7%) of the title product. MS (ESI): m / z = 443.2 [M+Na] + .
[0149] Step 7: 5-((tert-butyldiphenyldiphenyl)oxy)octahydrocyclopentadiene-1-carboxylate methyl(1h) 1 g (6.5 g, 15.5 mmol) was dissolved in methanol (65 mL), and 10% Pd / C (600 mg) was added under a nitrogen atmosphere. After several substitutions with hydrogen, the reaction mixture was carried out under a hydrogen atmosphere (15 psi) at room temperature for 3 hours with stirring. The reaction mixture was filtered, and the filtrate was concentrated to obtain the crude product (6.5 g), which is the title product 1h, and the next reaction was carried out directly. MS (ESI): m / z = 445.2 [M+Na] + .
[0150] Step 8: 5-Hydroxyoctahydrocyclopentadiene-1-carboxylate methyl(1i) 1h (6.3 g, 14.9 mmol) was dissolved in tetrahydrofuran (60 mL), and 1 M tetrabutylammonium fluoride tetrahydrofuran solution (16.4 mL, 16.4 mmol) was added. The mixture was reacted at room temperature for 3 hours. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 1i (2.1 g, yield 76.5%). 1 H NMR (400 MHz, CDCl3) δ 4.03 (tt, J = 9.8, 6.1 Hz, 1H), 3.65 (s, 3H), 2.75 - 2.61 (m, 2H), 2.50 - 2.38 (m, 1H), 2.26 - 2.15 (m, 1H), 2.02 - 1.88 (m, 2H), 1.83 - 1.74 (m, 2H), 1.66 - 1.49 (m, 2H), 1.22 - 1.07 (m, 2H).
[0151] Step 9: 2-methyl-6-(1-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-ol(1k) 3-Bromo-2-methyl-6-(1-methyl-5-((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine 1j (2.5 g, 6.81 mmol, prepared by the method disclosed in Example 1 of the specification in patent application WO2017223016A1), bis(dibenzylideneacetone)palladium (391 mg, 0.68 mmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (578 mg, 1.36 mmol), and potassium hydroxide (1.15 g, 20.44 mmol) were dissolved in 1,4-dioxane (50 mL) and water (10 mL) and allowed to stand at 100°C for 2 hours under a nitrogen atmosphere. The pH was adjusted to 6-7 with a 1 M hydrochloric acid solution, water (10 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. This crude product was then purified by diphenyl flash column chromatography (ethyl acetate / petroleum ether) to obtain 1 kJ of the title product (1.9 g, yield 92%). MS (ESI) m / z = 305.6 [M+H] + .
[0152] Step 10: 5-((2-methyl-6-(1-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylate methyl (1l) 1k (1 g, 3.29 mmol), triphenylphosphine (2.59 g, 9.86 mmol), and 1i (605 mg, 3.29 mmol) were dissolved in tetrahydrofuran (50 mL), heated to 50°C, and a solution of azodicarboxylate di-tert-butyl (2.25 g, 9.86 mmol) dissolved in tetrahydrofuran (10 mL) was gradually added dropwise. The mixture was reacted at 50°C for 2 hours with stirring. The mixture was concentrated under reduced pressure to obtain the crude product, which was purified by reverse-phase C18 column chromatography (acetonitrile / water) to obtain 1 liter (1.2 g, 77% yield) of the title product. MS (ESI) m / z = 471.8 [M+H] + .
[0153] Step 11: 5-((6-(5-(hydroxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylate methyl(1m) Dissolve 1 liter (1.2 g, 2.55 mmol) in methanol (30 mL), add p-toluenesulfonic acid hydrate (194 mg, 1.02 mmol), heat the reaction mixture to 70°C, and react under a nitrogen atmosphere for 2 hours. After cooling, concentrate under reduced pressure to obtain the title product, crude product 1 m (900 mg), which was used directly in the next reaction. MS (ESI) m / z = 387.7 [M+H] + .
[0154] Step 12: 5-((6-(5-(hydroxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (1n) 1 m (900 mg, 2.33 mmol) was dissolved in tetrahydrofuran (10 mL), methanol (10 mL), and water (10 mL), then lithium hydroxide (536 mg, 23.29 mmol) was added, and the mixture was reacted at room temperature for 3 hours. The pH was adjusted to 5-6 with 1 M hydrochloric acid solution, water (10 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the title product 1n (800 mg, yield 82%). MS (ESI) m / z = 373.6 [M+H] + .
[0155] Step 13: 5-((2-methyl-6-(1-methyl-5-(((4-(trifluoromethyl)pyrimidine-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (1) 1n (800 mg, 2.15 mmol) was dissolved in N,N-dimethylacetylamide (20 mL), and 60% sodium hydride (412 mg, 17.18 mmol) was added under ice bath. The mixture was reacted for 30 minutes, then 2-chloro-4-(trifluoromethyl)pyrimidine (588 mg, 3.22 mmol) was added, and the mixture was reacted with stirring at room temperature for 30 minutes. Water (10 mL) was added, the pH was adjusted to 4-5 with 1 M hydrochloric acid, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) and then freeze-dried to obtain the title product 1 (800 mg, yield 72%). MS (ESI) m / z = 519.8 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 4.9 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 4.9 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 6.10 (s, 2H), 5.02 - 4.94 (m, 1H), 4.16 (s, 3H), 2.94 - 2.84 (m, 1H), 2.78 - 2.64 (m, 2H), 2.15 (s, 3H), 2.13 - 2.04 (m, 1H), 1.91 - 1.81 (m, 1H), 1.73 - 1.55 (m, 3H), 1.52 - 1.34 (m, 3H).
[0156] [ka] Compound 1 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AS (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is isopropanol (0.1% aqueous ammonia), flow rate: 70 mL / min), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 1-P1 and 1-P2.
[0157] Compound 1-P1 has a relatively short retention time: MS m / z(ESI): 519.4[M+1] + Chiral SFC analysis: Retention time 2.962 minutes, chiral purity 100% (Column: Chiralpak AS-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is isopropanol (0.05% diethylamine)). 1 H NMR (400 MHz, DMSO-d6) δ 12.03 (s, 1H), 9.03 (d, J = 4.9 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 4.9 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 6.11 (s, 2H), 5.03 - 4.92 (m, 1H), 4.16 (s, 3H), 2.94 - 2.83 (m, 1H), 2.76 - 2.62 (m, 2H), 2.14 (s, 3H), 2.10 - 2.05 (m, 1H), 1.91 - 1.81 (m, 1H), 1.73 - 1.56 (m, 3H), 1.53 - 1.35 (m, 3H).
[0158] Compound 1-P2 has a relatively long retention time: MS m / z(ESI): 519.4[M+1] + Chiral SFC analysis: Retention time 3.461 minutes, chiral purity 99.1% (Column: Chiralpak AS-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is isopropanol (0.05% diethylamine)). 1H NMR (400 MHz, DMSO-d6) δ 12.04 (s, 1H), 9.03 (d, J = 4.9 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 4.9 Hz, 1H), 7.42 (d, J = 8.7 Hz, 1H), 6.11 (s, 2H), 5.01 - 4.92 (m, 1H), 4.16 (s, 3H), 2.98 - 2.82 (m, 1H), 2.77 - 2.62 (m, 2H), 2.14 (s, 3H), 2.11 - 2.04 (m, 1H), 1.90 - 1.81 (m, 1H), 1.72 - 1.55 (m, 3H), 1.51 - 1.35 (m, 3H).
[0159] Example 2 5-((6-(5-(((5-cyclopropyl-1,2,4-oxadiazole-3-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (2) [ka] [ka]
[0160] Step 1: (4-(5-bromo-6-methylpyridine-2-yl)-1-methyl-1H-1,2,3-triazole-5-yl)methanol (2a) 1 joule (31 g, 84.4 mmol) was dissolved in methanol (300 mL), and pyridine p-toluenesulfonate (31.8 g, 126.6 mmol) was added. The mixture was heated to 60°C and reacted with stirring for 1 hour. The reaction mixture was concentrated, water (150 mL) was added, and the mixture was extracted with ethyl acetate (300 mL x 3). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product (24 g), which is the title product 2a, and was used directly in the next reaction. MS (ESI): m / z = 283.4 [M+H] + .
[0161] Step 2: 3-((4-(5-bromo-6-methylpyridine-2-yl)-1-methyl-1H-1,2,3-triazole-5-yl)methoxy)-5-cyclopropyl-1,2,4-oxadiazole(2c) 2a (850 mg, 3.0 mmol) was dissolved in tetrahydrofuran (10 mL), cooled to 0°C, and 60% sodium hydride (240 mg, 6 mmol) was added. The mixture was reacted with stirring at 0°C for 30 minutes, after which 3-bromo-5-cyclopropyl-1,2,4-oxadiazole 2b (567.4 mg, 3.0 mmol) was added. The reaction mixture was returned to room temperature and reacted with stirring for 18 hours. Water (5 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 2c (700 mg, yield 59.6%). MS (ESI): m / z = 390.7 [M+H] + .
[0162] Step 3: 5-Cyclopropyl-3-((1-Methyl-4-(6-Methyl-5-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)Pyridine-2-yl)-1H-1,2,3-Triazolulan-5-yl)Methoxy)-1,2,4-Oxadiazole(2d) Under a nitrogen atmosphere, 2c (460 mg, 1.18 mmol) and bis(pinacolate)diborone (358.3 mg, 1.41 mmol) were dissolved in dioxane (5 mL), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (87.2 mg, 0.12 mmol) and potassium acetate (288.5 mg, 2.94 mmol) were added. The mixture was heated to 100°C and reacted for 12 hours. The reaction mixture was concentrated, and the residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 2d (200 mg, yield 38.8%). MS (ESI): m / z = 357.0 [M-82+H] + .
[0163] Step 4: 6-(5-(((5-cyclopropyl-1,2,4-oxadiazole-3-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-ol(2e) 2d (50.0 mg, 0.11 mmol) was dissolved in ethyl acetate (1 mL), and 30% hydrogen peroxide solution (0.11 mL, 1.14 mmol) was added. The mixture was reacted at room temperature for 1 hour. Saturated sodium sulfite solution (1 mL) was added to quench the mixture, and the solution was extracted with ethyl acetate (1 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 2e (20 mg, yield 53.4%). MS (ESI): m / z = 328.9 [M+H] + .
[0164] Step 5: 5-((6-(5-(((5-cyclopropyl-1,2,4-oxadiazole-3-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylate methyl(2f) 2e (100 mg, 0.31 mmol) and 1i (72.9 mg, 0.40 mmol) were dissolved in toluene (3 mL), triphenylphosphine (184.9 mg, 0.91 mmol) and 1,1'-(azodicarbonyl)dipiperidine (230.5 mg, 0.91 mmol) were added, and the reaction mixture was heated to 80°C and stirred for 12 hours. The reaction mixture was concentrated, and the residue was subjected to silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain the title product 2f (60 mg, yield 39.8%). MS (ESI): m / z = 495.3 [M+H] + .
[0165] Step 6: 5-((6-(5-(((5-cyclopropyl-1,2,4-oxadiazole-3-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (2) 2f (50 mg, 0.10 mmol) was dissolved in tetrahydrofuran (1 mL) and water (1 mL), lithium hydroxide monohydrate (12.7 mg, 0.30 mmol) was added, and the reaction was carried out at room temperature for 12 hours with stirring. The pH of the reaction mixture was adjusted to approximately 7 with 1 M hydrochloric acid solution, concentrated, and the residue was purified by preparative HPLC (acetonitrile / water) to obtain the title compound 2 (6.2 mg, yield 12.8%). MS (ESI): m / z = 481.2 [M+H] + . 1H NMR (400 MHz, CD3OD) δ 7.79 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 5.96 (s, 2H), 5.14 - 5.00 (m, 1H), 4.18 (s, 3H), 3.11 - 3.00 (m, 1H), 2.91 - 2.73 (m, 2H), 2.35 (s, 3H), 2.30 - 2.20 (m, 1H), 2.17 - 2.09 (m, 1H), 2.06 - 1.97 (m, 1H), 1.85 - 1.67 (m, 3H), 1.63 - 1.46 (m, 3H), 1.26 - 1.18 (m, 2H), 1.12 - 1.02 (m, 2H).
[0166] [ka] Compound 2 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AD (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia), flow rate: 80 mL / min), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 2-P1 and 2-P2.
[0167] Compound 2-P1 has a relatively short retention time: MS m / z(ESI): 481.2[M+H] + Chiral SFC analysis: Retention time 3.427 minutes, chiral purity 99.2% (Column: Chiralpak AD-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine)). 1H NMR (400 MHz, DMSO-d6) δ 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 5.94 (s, 2H), 5.04 - 4.90 (m, 1H), 4.12 (s, 3H), 2.97 - 2.81 (m, 1H), 2.76 - 2.64 (m, 2H), 2.25 (s, 3H), 2.23 - 2.17 (m, 1H), 2.15 - 2.07 (m, 1H), 1.91 - 1.82 (m, 1H), 1.72 - 1.58 (m, 3H), 1.52 - 1.34 (m, 3H), 1.25 - 1.17 (m, 2H), 1.05 - 0.99 (m, 2H).
[0168] Compound 2-P2は、Comparative long retention time:MS m / z(ESI):481.2[M+H] + , キラルSFC analysis: retention time 4.109 minutes, キラル purity 99.1% (カラム: Chiralpak AD-3, 0.46 cm ID × 150 mm, 3 μm, mobile phase: AはCO2, Bはエタノール (0.05%ジエチルアミン). 1 H NMR (400 MHz, DMSO-d6) δ 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 5.94 (s, 2H), 5.05 - 4.93 (m, 1H), 4.12 (s, 3H), 2.97 - 2.84 (m, 1H), 2.76 - 2.65 (m, 2H), 2.25 (s, 3H), 2.23 - 2.17 (m, 1H), 2.15 - 2.06 (m, 1H), 1.90 - 1.82 (m, 1H), 1.73 - 1.57 (m, 3H), 1.52 - 1.35 (m, 3H), 1.25 - 1.17 (m, 2H), 1.05 - 0.99 (m, 2H).
[0169] Example 3 5-((6-(5-(((4-(methoxymethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (3) [ka] [ka]
[0170] 1n (350 mg, 0.94 mmol) was dissolved in N,N-dimethylacetylamide (20 mL), and 60% sodium hydride (180 mg, 7.52 mmol) was added under ice bath. The mixture was reacted for 30 minutes, and 2-chloro-4-(methoxymethyl)pyrimidine (179 mg, 1.13 mmol) was added. The mixture was reacted at room temperature for 30 minutes. The mixture was diluted with water (10 mL), the pH was adjusted to 4-5 with 1 M hydrochloric acid, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase C18 column chromatography (acetonitrile / water) and then freeze-dried to obtain the title compound 3 (200 mg, yield 43%). MS (ESI) m / z = 495.5 [M+H] + .
[0171] [ka] Compound 3 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AS (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 3-P1 and 3-P2.
[0172] Compound 3-P1 has a relatively short retention time: MS m / z(ESI): 495.2[M+H] +Chiral SFC analysis: Retention time 2.717 minutes, chiral purity 100% (Column: Chiralpak AS-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine)). 1 H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 5.0 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 6.6 Hz, 2H), 6.16 - 6.01 (m, 2H), 4.86 (s, 1H), 4.36 (s, 2H), 4.18 (s, 3H), 3.45 (s, 3H), 3.15 - 2.98 (m, 1H), 2.91 - 2.77 (m, 2H), 2.34 (s, 3H), 2.30 - 2.21 (m, 1H), 2.09 - 2.00 (m, 1H), 1.87 - 1.77 (m, 2H), 1.75 - 1.64 (m, 1H), 1.57 - 1.40 (m, 3H).
[0173] Compound 3-P2 has a relatively long retention time: MS m / z(ESI): 495.2[M+H] + Chiral SFC analysis: Retention time 3.031 minutes, chiral purity 97.4% (Column: Chiralpak AS-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine)). 1H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 5.0 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.16 - 7.10 (m, 2H), 6.17 - 6.01 (m, 2H), 4.87 (s, 1H), 4.36 (s, 2H), 4.18 (s, 3H), 3.45 (s, 3H), 3.14 - 3.00 (m, 1H), 2.91 - 2.78 (m, 2H), 2.35 (s, 3H), 2.31 - 2.21 (m, 1H), 2.11 - 2.02 (m, 1H), 1.89 - 1.78 (m, 2H), 1.75 - 1.63 (m, 1H), 1.58 - 1.39 (m, 3H).
[0174] Example 4 5-((6-(5-(((6-ethylpyrimidine-4-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid(4) [ka] [ka]
[0175] Step 1: 4-Chloro-6-ethylpyrimidine (4b) 6-ethylpyrimidine-4-ol 4a (300 mg, 2.4 mmol) was dissolved in phosphorus oxychloride (3 mL) and reacted under a nitrogen atmosphere with heating for 3 hours. The remaining phosphorus oxychloride was removed under vacuum to obtain the crude product 4b (300 mg), which is the title compound, and was used directly in the next reaction. MS (ESI) m / z = 143.3 [M+H] + .
[0176] Step 2: 4-((4-(5-bromo-6-methylpyridine-2-yl)-1-methyl-1H-1,2,3-triazole-5-yl)methoxy)-6-ethylpyrimidine(4c) 2a (200 mg, 0.7 mmol) was dissolved in DMF (10 mL), and 60% sodium hydride (1.4 mmol, 56 mg) was added under ice bath. The reaction mixture was stirred under ice bath for 20 minutes, then 4b (121 mg, 0.85 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by flash column chromatography (ethyl acetate / petroleum ether) to obtain the title compound 4c (200 mg, yield 73%). MS (ESI) m / z = 389.5 [M+H] + .
[0177] Step 3: 6-(5-(((6-ethylpyrimidine-4-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-ol(4d) Under a nitrogen atmosphere, 4c (200 mg, 0.51 mmol), 1,1'-bisdiphenylphosphinoferocenedichloropalladium (38 mg, 0.05 mmol), and potassium hydroxide (86 mg, 1.5 mmol) were dissolved in 1,4-dioxane (5 mL) and water (1 mL), and the mixture was heated to 100°C and reacted with stirring for 3 hours. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by flash column chromatography (ethyl acetate / petroleum ether) to obtain the title compound 4d (150 mg, yield 89%). MS (ESI) m / z = 327.5 [M+H] + .
[0178] Step 4: 5-((6-(5-(((6-ethylpyrimidine-4-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylate methyl(4e) Under a nitrogen atmosphere, 4d (150 mg, 0.46 mmol), 1i (127 mg, 0.67 mmol), and triphenylphosphine (301 mg, 1.15 mmol) were dissolved in dry tetrahydrofuran (20 mL). The mixture was heated to 50°C, and a tetrahydrofuran solution of azodicarboxylate di-tert-butyl (262 mg, 1.15 mmol) (5 mL) was gradually added dropwise. After the addition was complete, the mixture was reacted at 50°C for 18 hours with stirring. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by flash column chromatography (ethyl acetate / petroleum ether) to obtain the title compound 4e (150 mg, 60% yield). MS (ESI) m / z = 493.7 [M+H] + .
[0179] Step 5: 5-((6-(5-(((6-ethylpyrimidine-4-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid(4) 4e (150 mg, 0.3 mmol) was dissolved in tetrahydrofuran (5 mL) and methanol (5 mL), lithium hydroxide monohydrate (128 mg, 3.05 mmol) and water (5 mL) were added, and the mixture was reacted at room temperature. Water (10 mL) was added, the pH was adjusted to 4-5 with 1 M hydrochloric acid, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) and then freeze-dried to obtain the title compound 4 (50 mg, yield 34%). MS (ESI) m / z = 479.7 [M+H] + .
[0180] [ka] Compound 4 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALCEL OJ (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia), flow rate: 70 mL / min), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 4-P1 and 4-P2.
[0181] Compound 4-P1 has a relatively short retention time: MS m / z(ESI): 479.2[M+H] + Chiral SFC analysis: Retention time 3.323 minutes, chiral purity 96.9% (Column: Chiralcel OJ-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.8 mL / min). 1 H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 6.63 (s, 1H), 6.13 - 6.03 (m, 2H), 4.93 - 4.87 (m, 1H), 4.14 (s, 3H), 3.14 - 3.02 (m, 1H), 2.91 - 2.80 (m, 2H), 2.71 (q, J = 7.6 Hz, 2H), 2.34 (s, 3H), 2.32 - 2.23 (m, 1H), 2.14 - 2.04 (m, 1H), 1.88 - 1.67 (m, 3H), 1.61 - 1.40 (m, 3H), 1.25 (t, J = 7.6 Hz, 3H).
[0182] Compound 4-P2 has a relatively long retention time: MS m / z(ESI): 479.2[M+H] +Chiral SFC analysis: Retention time 4.303 minutes, chiral purity 100% (Column: Chiralcel OJ-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.8 mL / min). 1 H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.63 (d, J = 1.0 Hz, 1H), 6.14 - 5.99 (m, 2H), 4.91 - 4.86 (m, 1H), 4.14 (s, 3H), 3.14 - 3.01 (m, 1H), 2.91 - 2.79 (m, 2H), 2.71 (q, J = 7.6 Hz, 2H), 2.34 (s, 3H), 2.32 - 2.23 (m, 1H), 2.13 - 2.03 (m, 1H), 1.88 - 1.66 (m, 3H), 1.61 - 1.40 (m, 3H), 1.24 (t, J = 7.6 Hz, 3H).
[0183] Example 5 1-Fluoro-5-((6-(5-(((4-(methoxymethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid(5) [ka] [ka]
[0184] Step 1: 5-((tert-butyldiphenyldiphenyl)oxy)-1-fluoro-octahydrocyclopentadiene-1-carboxylate methyl(5a) Dissolve 1h (1700 mg, 4.02 mmol) in anhydrous tetrahydrofuran (50 mL), cool to -78°C, add LDA (4 mL, 2 M in THF) to the reaction mixture, and react at the same temperature for 30 minutes. Add N-fluorobisbenzenesulfonamide (2536 mg, 48.04 mmol), gradually raise the temperature to room temperature, and react for 16 hours. Add saturated ammonium chloride solution to the reaction mixture and extract with ethyl acetate (20 mL x 2). Combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate to obtain the crude product. The crude product is purified by reverse-phase flash column chromatography (acetonitrile / water) and then freeze-dried to obtain 5a (1400 mg, yield 79%). MS (ESI) m / z = 441.3 [M+H] + .
[0185] Step 2: 1-Fluoro-5-hydroxyoctahydrocyclopentadiene-1-carboxylate methyl(5b) 5a (1300 mg, 2.95 mmol) was dissolved in tetrahydrofuran (30 mL), and tetrabutylammonium fluoride solution (4.42 mL, 1 M in THF) was added to the reaction mixture. The mixture was reacted at room temperature for 2 hours. The solvent was concentrated under reduced pressure to obtain the crude product, which was then purified by flash column chromatography (petroleum ether / ethyl acetate) to obtain 5b (400 mg, 67% yield).
[0186] Step 3: 1-Fluoro-5-((2-methyl-6-(1-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylate methyl(5c) 5b (399 mg, 1.97 mmol), 1k (600 mg, 1.97 mmol), and triphenylphosphine (1293 mg, 4.93 mmol) were dissolved in tetrahydrofuran (50 mL), heated to 50°C, and a solution of azodicarboxylate di-tert-butyl (1125 mg, 4.93 mmol) dissolved in tetrahydrofuran (10 mL) was added dropwise. The mixture was reacted at 50°C for 2 hours. The mixture was concentrated under reduced pressure to obtain the crude product, which was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain a pale yellow oily substance 5c (600 mg, yield 62%). MS (ESI) m / z = 489.4 [M+H] + .
[0187] Step 4: 1-Fluoro-5-((6-(5-(hydroxymethyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylate methyl(5d) 5c (600 mg, 1.23 mmol) was dissolved in methanol (30 mL), and p-toluenesulfonic acid monohydrate (117 mg, 0.61 mmol) was added. The mixture was heated to 70°C and reacted under a nitrogen atmosphere for 2 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure to obtain crude product 5d (450 mg), which was then used in the next reaction. MS (ESI) m / z = 405.7 [M+H] + .
[0188] Step 5: 1-Fluoro-5-((6-(5-(hydroxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (5e) 5d (450 mg, 1.11 mmol) was dissolved in tetrahydrofuran (3 mL), methanol (3 mL), and water (3 mL), and lithium hydroxide (140 mg, 3.34 mmol) was added. The mixture was reacted at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the crude product, which was purified by reverse-phase flash column chromatography (water / acetonitrile) to obtain 5e (380 mg, 87% yield). MS (ESI) m / z = 391.3 [M+H] + .
[0189] Step 6: 1-Fluoro-5-((6-(5-(((4-(methoxymethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (5) 5e (130 mg, 0.33 mmol) was dissolved in N,N-dimethylacetylamide (10 mL), and 60% sodium hydride (107 mg, 2.66 mmol) was added under ice bath. The mixture was reacted for 30 minutes, and 2-chloro-4-(methoxymethyl)pyrimidine (106 mg, 0.67 mmol) was added. The mixture was reacted at room temperature for 30 minutes. The solution was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 4-5, and the solution was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain compound 5 (80 mg, yield 47%). MS (ESI) m / z = 513.9 [M+H] + .
[0190] [ka] Compound 5 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AD (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia), flow rate: 70 mL / min), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 5-P1 and 5-P2.
[0191] Compound 5-P1 has a relatively short retention time: MS m / z(ESI): 513.2[M+H] + Chiral SFC analysis: Retention time 5.535 minutes, chiral purity 99.3% (Column: Chiralpak AD-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.62 (d, J = 5.0 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.16 (d, J = 5.0 Hz, 1H), 6.00 (s, 2H), 5.09 - 4.89 (m, 1H), 4.35 (s, 2H), 4.13 (s, 3H), 3.36 (s, 3H), 2.93 - 2.68 (m, 2H), 2.20 (s, 3H), 2.17 - 2.06 (m, 2H), 1.97 - 1.82 (m, 3H), 1.70 - 1.47 (m, 3H).
[0192] Compound 5-P2 has a relatively long retention time: MS m / z(ESI): 513.3[M+H] + Chiral SFC analysis: Retention time 6.103 minutes, chiral purity 98.6% (Column: Chiralpak AD-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1H NMR (400 MHz, DMSO-d6) δ 8.62 (d, J = 5.0 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.16 (d, J = 5.0 Hz, 1H), 6.00 (s, 2H), 5.17 - 4.89 (m, 1H), 4.35 (s, 2H), 4.13 (s, 3H), 3.36 (s, 3H), 2.89 - 2.63 (m, 2H), 2.19 (s, 3H), 2.19 - 2.03 (m, 2H), 1.92 - 1.78 (m, 3H), 1.74 - 1.65 (m, 1H), 1.59 - 1.45 (m, 2H).
[0193] Example 6 5-((6-(5-(((4-(difluoromethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)-1-fluorooctahydrocyclopentadiene-1-carboxylic acid (6) [ka] [ka]
[0194] Step 1: 4-(difluoromethyl)pyrimidine-2-ol (6b) Difluoroacetic anhydride (4823 mg, 27.74 mmol) was dissolved in anhydrous dichloromethane (30 mL), cooled to -20°C, and 4-dimethylaminopyridine (17 mg, 0.14 mmol) was added, followed by 6a (1000 mg, 13.87 mmol). The temperature was controlled not to exceed -10°C during addition. The mixture was then gradually raised to room temperature and reacted for 16 hours. The mixture was washed with saturated sodium bicarbonate solution, the dichloromethane layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain an oily substance. The oily substance was dissolved in ethanol (50 mL), and urea (1666 mg, 27.74 mmol) and concentrated hydrochloric acid (12 mL) were added under an ice bath. After the addition was complete, the mixture was raised to room temperature and reacted for 16 hours. The solvent was concentrated and removed under reduced pressure, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain 6b (1500 mg, yield 74%). MS (ESI) m / z = 147.3 [M+H] + .
[0195] Step 2: 2-Chloro-4-(difluoromethyl)pyrimidine (6c) 6b (1500 mg, 10.27 mmol) was dissolved in phosphorus oxychloride (10 mL), and the mixture was heated to 105°C and reacted for 2 hours. The solvent was removed under reduced pressure, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain crude product 6c (700 mg, yield 41%). MS (ESI) m / z = 165.2 [M+H] + .
[0196] Step 3: 5-((6-(5-(((4-(difluoromethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)-1-fluorooctahydrocyclopentadiene-1-carboxylic acid (6) 5e (130 mg, 0.33 mmol) was dissolved in N,N-dimethylacetylamide (10 mL), and 60% sodium hydride (107 mg, 2.66 mmol) was added under ice bath. The mixture was reacted for 30 minutes, and 6c (71 mg, 0.43 mmol) was added. The mixture was reacted at room temperature for 30 minutes. The solution was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 4-5, and the solution was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain title compound 6 (20 mg, yield 11%). MS (ESI) m / z = 519.8 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 4.9 Hz, 1H), 7.91 (d, J = 8.6 Hz, 1H), 7.29 - 7.26 (m, 1H), 7.11 (d, J = 8.6 Hz, 1H), 6.43 - 6.09 (m, 3H), 4.92 - 4.82 (m, 1H), 4.19 (s, 3H), 3.08 - 2.92 (m, 2H), 2.38 - 2.26 (m, 4H), 2.17 - 1.96 (m, 3H), 1.80 - 1.68 (m, 1H), 1.65 - 1.47 (m, 2H), 1.35 - 1.25 (m, 1H).
[0197] Example 7 5-((6-(5-(((4-(difluoromethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (7) [ka] [ka]
[0198] 1n (100 mg, 0.27 mmol) was dissolved in N,N-dimethylacetylamide (10 mL), and 60% sodium hydride (86 mg, 2.15 mmol) was added under ice bath. The mixture was reacted for 30 minutes, and 6c (88 mg, 0.54 mmol) was added. The mixture was reacted at room temperature for 30 minutes. The solution was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 4-5, and the solution was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain the title compound 7 (10 mg, yield 7.4%). MS (ESI) m / z = 501.5 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 4.9 Hz, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.29 - 7.27 (m, 1H), 7.14 (d, J = 8.5 Hz, 1H), 6.41 - 6.11 (m, 3H), 4.92 - 4.86 (m, 1H), 4.19 (s, 3H), 3.14 - 3.02 (m, 1H), 2.93 - 2.80 (m, 2H), 2.34 (s, 3H), 2.32 - 2.23 (m, 1H), 2.13 - 2.04 (m, 1H), 1.89 - 1.80 (m, 3H), 1.76 - 1.62 (m, 3H).
[0199] Example 8 5-((2-methyl-6-(1-methyl-5-(((4-(((R)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid(8) [ka] [ka]
[0200] Step 1: (R)-2-chloro-4-((tetrahydrofuran-3-yl)oxy)pyrimidine (8b) 2,4-Dichloropyrimidine 8a (1000 mg, 6.71 mmol) and (3R)-3-hydroxytetrahydrofuran (710 mg, 8.05 mmol) were dissolved in N,N-dimethylformamide (10 mL), and cesium carbonate (4374 mg, 13.43 mmol) was added to the reaction mixture. The reaction mixture was heated to 70°C and reacted for 2 hours. Water was added to the reaction mixture, and it was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by flash column chromatography (petroleum ether / ethyl acetate) to obtain 8b (1200 mg, yield 89%). MS (ESI) m / z = 201.2 [M+H] + .
[0201] Step 2: 5-((2-methyl-6-(1-methyl-5-(((4-(((R)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (8) 1n (110 mg, 0.3 mmol) was dissolved in N,N-dimethylacetylamide (10 mL), 60% sodium hydride (94 mg, 2.36 mmol) was added under ice bath, and the mixture was reacted for 30 minutes. Then 8b (76 mg, 0.38 mmol) was added, and the mixture was reacted at room temperature for 30 minutes. The mixture was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 4-5, and the solution was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain title compound 8 (75 mg, yield 47%). MS (ESI) m / z = 537.6 [M+H] + .
[0202] [ka] Compound 8 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AS (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 8-P1 and 8-P2.
[0203] Compound 8-P1 has a relatively short retention time: MS m / z(ESI): 537.3[M+H] + Chiral SFC analysis: Retention time 4.707 minutes, chiral purity 97.4% (Column: Chiralpak AS-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 5.7 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 6.60 (d, J = 5.7 Hz, 1H), 6.00 (s, 2H), 5.46 - 5.37 (m, 1H), 5.04 - 4.91 (m, 1H), 4.11 (s, 3H), 3.87 - 3.64 (m, 4H), 2.94 - 2.82 (m, 1H), 2.76 - 2.63 (m, 2H), 2.22 (s, 3H), 2.17 - 2.04 (m, 2H), 1.99 - 1.81 (m, 2H), 1.76 - 1.54 (m, 3H), 1.52 - 1.35 (m, 3H).
[0204] Compound 8-P2 has a relatively long retention time: MS m / z(ESI): 537.3[M+H] +Chiral SFC analysis: Retention time 5.541 minutes, chiral purity 97.1% (Column: Chiralpak AS-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 5.7 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 6.60 (d, J = 5.7 Hz, 1H), 6.01 (s, 2H), 5.45 - 5.39 (m, 1H), 5.01 - 4.90 (m, 1H), 4.11 (s, 3H), 3.86 - 3.67 (m, 4H), 2.95 - 2.82 (m, 1H), 2.77 - 2.64 (m, 2H), 2.22 (s, 3H), 2.17 - 2.05 (m, 2H), 2.01 - 1.91 (m, 1H), 1.90 - 1.81 (m, 1H), 1.74 - 1.57 (m, 3H), 1.53 - 1.36 (m, 3H).
[0205] Example 9 5-((2-methyl-6-(1-methyl-5-(((4-(((S)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid(9) [ka] [ka]
[0206] Step 1: (S)-2-chloro-4-((tetrahydrofuran-3-yl)oxy)pyrimidine (9a) 2,4-Dichloropyrimidine 8a (1000 mg, 6.71 mmol) and (3S)-3-hydroxytetrahydrofuran (710 mg, 8.05 mmol) were dissolved in N,N-dimethylformamide (10 mL), and cesium carbonate (4374 mg, 13.43 mmol) was added to the reaction mixture. The reaction mixture was heated to 70°C and reacted for 2 hours. Water was added to the reaction mixture, and it was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by flash column chromatography (petroleum ether / ethyl acetate) to obtain 9a (1200 mg, yield 89%). MS (ESI) m / z = 201.2 [M+H] + .
[0207] Step 2: 5-((2-methyl-6-(1-methyl-5-(((4-(((S)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (9) 1n (110 mg, 0.3 mmol) was dissolved in N,N-dimethylacetylamide (10 mL), and 60% sodium hydride (94 mg, 2.36 mmol) was added under ice bath. The mixture was reacted for 30 minutes, and 9a (76 mg, 0.38 mmol) was added. The mixture was reacted at room temperature for 30 minutes. The solution was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 4-5, and the solution was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain the title compound 9 (75 mg, yield 47%). MS (ESI) m / z = 537.5 [M+H] + .
[0208] [ka] Compound 9 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AS (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 9-P1 and 9-P2.
[0209] Compound 9-P1 has a relatively short retention time: MS m / z(ESI): 537.3[M+H] + Chiral SFC analysis: Retention time 3.704 minutes, chiral purity 98.2% (Column: Chiralpak AS-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 5.7 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.7 Hz, 1H), 6.60 (d, J = 5.7 Hz, 1H), 6.09 - 5.90 (m, 2H), 5.47 - 5.39 (m, 1H), 5.01 - 4.95 (m, 1H), 4.11 (s, 3H), 3.84 - 3.66 (m, 4H), 2.94 - 2.83 (m, 1H), 2.77 - 2.63 (m, 2H), 2.22 (s, 3H), 2.18 - 2.05 (m, 2H), 1.99 - 1.91 (m, 1H), 1.90 - 1.81 (m, 1H), 1.73 - 1.55 (m, 3H), 1.51 - 1.36 (m, 3H).
[0210] Compound 9-P2 has a relatively long retention time: MS m / z(ESI): 537.3[M+H] + Chiral SFC analysis: Retention time 4.1801 minutes, chiral purity 95.6% (Column: Chiralpak AS-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 5.7 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.43 (d, J = 8.7 Hz, 1H), 6.60 (d, J = 5.6 Hz, 1H), 6.00 (s, 2H), 5.46 - 5.38 (m, 1H), 5.01 - 4.92 (m, 1H), 4.11 (s, 3H), 3.84 - 3.64 (m, 4H), 2.96 - 2.81 (m, 1H), 2.76 - 2.62 (m, 2H), 2.22 (s, 3H), 2.18 - 2.05 (m, 2H), 2.00 - 1.90 (m, 1H), 1.90 - 1.80 (m, 1H), 1.72 - 1.54 (m, 3H), 1.52 - 1.36 (m, 3H).
[0211] Example 10 5-((6-(5-(((4-(2-hydroxypropane-2-yl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (10) [ka] [ka]
[0212] Step 1: 2-(2-chloropyrimidine-4-yl)propan-2-ol (10b) 2-chloropyrimidine-4-carboxylate methyl 10a (400 mg, 3.32 mmol) was dissolved in anhydrous tetrahydrofuran (30 mL), cooled to 0°C, and methylmagnesium bromide (1.9 mL, 5.80 mmol) was added. The mixture was reacted for 1 hour. Saturated ammonium chloride was added to the reaction mixture and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by flash column chromatography (petroleum ether / ethyl acetate) to obtain 10b (350 mg, yield 87%). MS (ESI) m / z = 173.3 [M+H] + .
[0213] Step 2: 5-((6-(5-(((4-(2-hydroxypropane-2-yl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (10) 1n (100 mg, 0.27 mmol) was dissolved in N,N-dimethylacetylamide (10 mL), and 60% sodium hydride (86 mg, 2.15 mmol) was added under ice bath. The mixture was reacted for 30 minutes, and 10b (70 mg, 0.40 mmol) was added. The mixture was reacted at room temperature for 30 minutes. The solution was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 4-5, and the solution was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain the title compound 10 (80 mg, yield 58%). MS (ESI) m / z = 509.7 [M+H] + .
[0214] [ka] SFC chiral preparative separation of compound 10 was performed (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AS (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia), flow rate 70 mL / min), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 10-P1 and 10-P2.
[0215] Compound 10-P1 has a relatively short retention time: MS m / z(ESI): 509.2[M+H] + Chiral SFC analysis: Retention time 2.971 minutes, chiral purity 97.9% (Column: Chiralpak AS-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.8 mL / min). 1 H NMR (400 MHz, CD3OD) δ 8.52 (d, J = 5.2 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.43 - 7.33 (m, 2H), 6.13 (s, 2H), 5.06 - 4.96 (m, 1H), 4.22 (s, 3H), 3.11 - 3.00 (m, 1H), 2.91 - 2.76 (m, 2H), 2.35 (s, 3H), 2.31 - 2.20 (m, 1H), 2.08 - 1.98 (m, 1H), 1.91 - 1.68 (m, 3H), 1.65 - 1.49 (m, 3H), 1.33 (s, 6H).
[0216] Compound 10-P2 has a relatively long retention time: MS m / z(ESI): 509.3[M+H] + Chiral SFC analysis: Retention time 3.310 minutes, chiral purity 95.4% (Column: Chiralpak AS-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.8 mL / min). 1H NMR (400 MHz, CD3OD) δ 8.52 (d, J = 5.2 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.40 - 7.35 (m, 2H), 6.13 (s, 2H), 5.03 - 4.96 (m, 1H), 4.22 (s, 3H), 3.11 - 2.98 (m, 1H), 2.90 - 2.76 (m, 2H), 2.35 (s, 3H), 2.29 - 2.20 (m, 1H), 2.08 - 1.97 (m, 1H), 1.89 - 1.67 (m, 3H), 1.64 - 1.49 (m, 3H), 1.33 (s, 6H).
[0217] Example 11 5-((6-(5-(((4-methoxypyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (11) [ka] [ka]
[0218] 1n (100 mg, 0.27 mmol) was dissolved in N,N-dimethylacetylamide (10 mL), and 60% sodium hydride (86 mg, 2.15 mmol) was added under ice bath. The mixture was reacted for 30 minutes, and 2-chloro-4-methoxypyrimidine (51 mg, 0.35 mmol) was added. The mixture was reacted at room temperature for 30 minutes. The solution was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 4-5, and the solution was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain title compound 11 (80 mg, yield 62%). MS (ESI) m / z = 481.5 [M+H] + .
[0219] [ka] Compound 11 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK IG (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 11-P1 and 11-P2.
[0220] Compound 11-P1 has a relatively short retention time: MS m / z(ESI): 481.2[M+H] + Chiral SFC analysis: Retention time 0.731 minutes, chiral purity 100% (Column: Chiralcel OJ-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.8 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.33 (d, J = 5.7 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 6.61 (d, J = 5.7 Hz, 1H), 6.01 (s, 2H), 5.01 - 4.92 (m, 1H), 4.12 (s, 3H), 3.80 (s, 3H), 2.92 - 2.82 (m, 1H), 2.77 - 2.65 (m, 2H), 2.22 (s, 3H), 2.14 - 2.05 (m, 1H), 1.90 - 1.81 (m, 1H), 1.72 - 1.54 (m, 3H), 1.51 - 1.36 (m, 3H).
[0221] Compound 11-P2 has a relatively long retention time: MS m / z(ESI): 481.2[M+H] +Chiral SFC analysis: Retention time 0.969 minutes, chiral purity 99.6% (Column: Chiralcel OJ-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.8 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.33 (d, J = 5.7 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.7 Hz, 1H), 6.61 (d, J = 5.7 Hz, 1H), 6.01 (s, 2H), 5.00 - 4.94 (m, 1H), 4.12 (s, 3H), 3.80 (s, 3H), 2.94 - 2.81 (m, 1H), 2.76 - 2.63 (m, 2H), 2.22 (s, 3H), 2.17 - 2.06 (m, 1H), 1.90 - 1.81 (m, 1H), 1.74 - 1.55 (m, 3H), 1.52 - 1.36 (m, 3H).
[0222] Example 12 (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((4-(trifluoromethyl)pyrimidine-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)cyclohexane-1-carboxylic acid (12) [ka] [ka]
[0223] 12a (550 mg, 1.59 mmol) (obtained by the synthesis method of Intermediate 43 in patent WO2019126093 A1) was dissolved in N,N-dimethylacetylamide (20 mL), 60% sodium hydride (305 mg, 12.7 mmol) was added under ice bath, and the mixture was reacted for 30 minutes. Then 2-chloro-4-trifluoromethylpyrimidine (434 mg, 2.38 mmol) was added, and the mixture was reacted at room temperature. The mixture was diluted with water (10 mL), the pH of 1 M hydrochloric acid was adjusted to 5-6, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was purified by reverse-phase flash column chromatography (acetonitrile / water) to obtain the title compound 12 (523 mg, yield 67%). MS (ESI) m / z = 493.4 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 12.18 (s, 1H), 9.03 (d, J = 4.9 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 4.9 Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 6.12 (s, 2H), 4.76 (s, 1H), 4.16 (s, 3H), 2.68 - 2.55 (m, 1H), 2.20 (s, 3H), 2.05 - 1.94 (m, 1H), 1.89 - 1.70 (m, 3H), 1.67 - 1.40 (m, 4H).
[0224] Example 13 5-((6-(5-(((4-(ethoxymethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (13) [ka] [ka]
[0225] The title compound 13 was obtained by replacing "2-chloro-4-(methoxymethyl)pyrimidine," a raw material in Example 3, with "2-chloro-4-(ethoxymethyl)pyrimidine" during synthesis. MS (ESI) m / z = 509.2 [M+H] + .
[0226] [ka] Compound 13 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK IG (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 13-P1 and 13-P2.
[0227] Compound 13-P1 has a relatively short retention time: MS m / z(ESI): 509.2[M+H] + Chiral SFC analysis: Retention time 4.544 minutes, chiral purity 100% (Column: Chiralpak IG-3, 0.46 cm ID × 100 mm, 3 μm, Mobile phase: A is CO2, B is isopropanol (0.05% diethylamine), flow rate 2.8 mL / min). 1H NMR (400 MHz, CD3OD) δ 8.52 (d, J = 5.0 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.5 Hz, 1H), 7.21 (d, J = 5.1 Hz, 1H), 6.06 (s, 2H), 4.99 (s, 1H), 4.34 (s, 2H), 4.23 (s, 3H), 3.59 (q, J = 7.0 Hz, 2H), 3.10 - 2.99 (m, 1H), 2.89 - 2.76 (m, 2H), 2.35 (s, 3H), 2.29 - 2.21 (m, 1H), 2.07 - 1.98 (m, 1H), 1.88 - 1.69 (m, 3H), 1.66 - 1.49 (m, 3H), 1.25 (t, J = 7.0 Hz, 3H).
[0228] Compound 13-P2, comparative long retention time: MS m / z (ESI): 509.2 [M+H] + , キラルSFC analysis: retention time 5.903 minutes, キラル purity 100% (カラム: Chiralpak IG-3, 0.46 cm ID × 100 mm, 3 μm, mobile phase: AはCO2, Bはイソプロパノール (0.05% ジエチルアミン), flow rate 2.8 mL / min. 1 H NMR (400 MHz, CD3OD) δ 8.52 (d, J = 5.1 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 7.21 (d, J = 5.0 Hz, 1H), 6.06 (s, 2H), 4.99 (s, 1H), 4.35 (s, 2H), 4.23 (s, 3H), 3.59 (q, J = 7.0 Hz, 2H), 3.11 - 3.01 (m, 1H), 2.89 - 2.78 (m, 2H), 2.35 (s, 3H), 2.30 - 2.20 (m, 1H), 2.07 - 1.98 (m, 1H), 1.87 - 1.49 (m, 6H), 1.25 (t, J = 7.0 Hz, 3H).
[0229] Example 14 5-((6-(5-(((4-(methoxymethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)-1-methyloctahydrocyclopentadiene-1-carboxylic acid (14) [ka] [ka]
[0230] Step 1: 5-((tert-butyldiphenyldiphenyl)oxy)-1-methyloctahydrocyclopentadiene-1-carboxylate methyl(14a) Dissolve 1h (1.2 g, 2.84 mmol) in dry tetrahydrofuran (30 mL), cool to -78°C, add 2 M diisopropylaminolithium (4 mL, 8 mmol) dropwise, and react with stirring at 0°C for 30 minutes. Then add iodomethane (1.2 g, 8.52 mmol) and react at room temperature. Quench the reaction with aqueous ammonium chloride, concentrate the reaction mixture, and purify the crude product by reverse-phase flash column chromatography (acetonitrile / water) to obtain 14a (900 mg, yield 72%). MS (ESI) m / z = 437.4 [M+H] + .
[0231] Step 2: 5-hydroxy-1-methyloctahydrocyclopentadiene-1-carboxylate methyl(14b) 14a (1 g, 2.29 mmol) was dissolved in tetrahydrofuran (100 mL), and 1 M tetrabutylammonium fluoride tetrahydrofuran solution (4.6 mL, 4.6 mmol) was added. The mixture was reacted at room temperature for 5 hours. The reaction mixture was concentrated, and the residue was purified by silica gel flash column chromatography (petroleum ether / ethyl acetate) to obtain 14b (200 mg, yield 44%).
[0232] Step 3: 1-Methyl-5-((2-methyl-6-(1-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazole-4-yl)pyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylate methyl(14c) 1k (230 mg, 0.76 mmol), triphenylphosphine (597 g, 2.27 mmol), and 14b (150 mg, 0.76 mmol) were dissolved in tetrahydrofuran (100 mL), heated to 50°C, and a solution of azodicarboxylate di-tert-butyl (522 mg, 2.27 mmol) dissolved in tetrahydrofuran (10 mL) was gradually added dropwise. The mixture was reacted at 50°C for 2 hours with stirring. The mixture was concentrated under reduced pressure to obtain the crude product, which was purified by reverse-phase C18 column chromatography (acetonitrile / water) to obtain 14c (180 mg, 49% yield). MS (ESI) m / z = 485.3 [M+H] + .
[0233] Step 4: 5-((6-(5-(hydroxymethyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)-1-methyloctahydrocyclopentadiene-1-carboxylate methyl(14d) 14c (230 mg, 0.48 mmol) was dissolved in methanol (30 mL), p-toluenesulfonic acid hydrate (45 mg, 0.24 mmol) was added, and the reaction mixture was heated to 70°C and reacted under a nitrogen atmosphere for 2 hours. After cooling and concentration under reduced pressure, the crude product 14d (160 mg), the title product, was obtained and used directly in the next reaction. MS (ESI) m / z = 401.3 [M+H] + .
[0234] Step 5: 5-((6-(5-(hydroxymethyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)-1-methyloctahydrocyclopentadiene-1-carboxylic acid (14e) 14d (160 mg, 0.4 mmol) was dissolved in tetrahydrofuran (3 mL), methanol (3 mL), and water (3 mL), then lithium hydroxide (84 mg, 1.99 mmol) was added and the mixture was reacted at room temperature. The reaction mixture was concentrated to obtain the crude product, which was purified by reverse-phase C18 column chromatography (acetonitrile / water) to obtain 14e (130 mg, yield 84%). MS (ESI) m / z = 387.2 [M+H] + .
[0235] Step 6: 5-((6-(5-(((4-(methoxymethyl)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)-1-methyloctahydrocyclopentadiene-1-carboxylic acid (14) Dissolve 14e (130 mg, 0.33 mmol) in N,N-dimethylacetylamide (10 mL), add 60% sodium hydride (108 mg, 2.69 mmol) under ice bath, and react for 30 minutes. Then add 2-chloro-4-(methoxymethyl)pyrimidine (107 mg, 0.67 mmol) and react with stirring at room temperature for 30 minutes. Add water (10 mL) to adjust the pH of 1 M hydrochloric acid to 5-6, and extract with ethyl acetate (20 mL x 3). Combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate to obtain the crude product. The crude product is purified by reverse-phase flash column chromatography (acetonitrile / water) and then freeze-dried to obtain the title product 14 (38 mg, yield 22%). MS (ESI) m / z = 509.5 [M+H] + .
[0236] [ka] Compound 14 was subjected to SFC chiral preparative separation (separation conditions: SFC chiral preparative column DAIEL CHIRALPAK AD (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is ethanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 14-P1 and 14-P2.
[0237] Compound 14-P1 has a relatively short retention time: MS m / z(ESI): 509.2[M+H] + Chiral SFC analysis: Retention time 3.190 minutes, chiral purity 99.9% (Column: Chiralpak AD-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1 H NMR (400 MHz, DMSO-d6) δ 8.62 (d, J = 5.0 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 8.7 Hz, 1H), 7.16 (d, J = 5.0 Hz, 1H), 6.00 (s, 2H), 4.95 (s, 1H), 4.36 (s, 2H), 4.13 (s, 3H), 3.37 (s, 3H), 2.69 - 2.65 (m, 2H), 2.34 - 2.31 (m, 2H), 2.20 (s, 3H), 2.15 - 1.83 (m, 3H), 1.58 - 1.31 (m, 3H), 1.18 (s, 3H).
[0238] Compound 14-P2 has a relatively long retention time: MS m / z(ESI): 509.2[M+H] + Chiral SFC analysis: Retention time 4.538 minutes, chiral purity 99.3% (Column: Chiralpak AD-3, 0.46 cm ID × 150 mm, 3 μm, Mobile phase: A is CO2, B is ethanol (0.05% diethylamine), flow rate 2.5 mL / min). 1H NMR (400 MHz, DMSO-d6) δ 8.62 (d, J = 5.0 Hz, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.16 (d, J = 5.0 Hz, 1H), 6.00 (s, 2H), 4.95 (s, 1H), 4.36 (s, 2H), 4.13 (s, 3H), 3.37 (s, 3H), 2.69 - 2.66 (m, 2H), 2.36 - 2.31 (m, 2H), 2.20 (s, 3H), 2.13 - 1.80 (m, 3H), 1.57 - 1.30 (m, 3H), 1.18 (s, 3H).
[0239] Example 15 5-((6-(5-(((5-fluoro-4-(((R)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (15) [ka]
[0240] Compound 15 was prepared according to the preparation method in Example 8, and SFC chiral preparative separation of compound 15 was performed (separation conditions: SFC chiral preparative column ChiralPak IH (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is isopropanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 15-P1 and 15-P2.
[0241] Compound 15-P1 has a relatively short retention time: LC-MS(ESI) m / z = 555.3 [M + H] +Chiral SFC analysis: Retention time 1.278 minutes, chiral purity 100% (Column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, Mobile phase: A is CO2, B is isopropanol (0.1% isopropylamine), Flow rate 3.4 mL / min, Column temperature 35°C). 1 H NMR (400 MHz, CD3OD) δ 8.21 (d, J = 2.7 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.39 (d, J = 8.6 Hz, 1H), 6.12 - 5.97 (m, 2H), 5.46 - 5.39 (m, 1H), 4.99 (s, 1H), 4.20 (s, 3H), 3.98 - 3.77 (m, 4H), 3.14 - 2.98 (m, 1H), 2.88 - 2.76 (m, 2H), 2.37 (s, 3H), 2.28 - 1.98 (m, 4H), 1.88 - 1.66 (m, 3H), 1.67 - 1.47 (m, 3H).
[0242] Compound 15-P2 has a relatively long retention time: LC-MS(ESI) m / z = 555.2 [M + H] + Chiral SFC analysis: Retention time 1.507 minutes, chiral purity 100% (Column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, Mobile phase: A is CO2, B is isopropanol (0.1% isopropylamine), Flow rate 3.4 mL / min, Column temperature 35°C). 1H NMR (400 MHz, CD3OD) δ 8.20 (d, J = 2.4 Hz, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 6.10 - 5.97 (m, 2H), 5.45 (s, 1H), 4.97 (s, 1H), 4.21 (s, 3H), 3.97 - 3.74 (m, 4H), 3.11 - 3.00 (m, 1H), 2.88 - 2.76 (m, 2H), 2.38 (s, 3H), 2.27 - 1.97 (m, 4H), 1.86 - 1.44 (m, 6H).
[0243] Example 16 5-((6-(5-(((5-chloro-4-(((R)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (16) [ka]
[0244] Compound 16 was prepared according to the preparation method in Example 8, and SFC chiral preparative separation of compound 16 was performed (separation conditions: SFC chiral preparative column ChiralPak IH (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is isopropanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 16-P1 and 16-P2.
[0245] Compound 16-P1 has a relatively short retention time: LC-MS(ESI) m / z = 571.2 [M + H] + Chiral SFC analysis, retention time 1.321 minutes, chiral purity 100% (column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, mobile phase: A is CO2, B is isopropanol (0.1% isopropylamine), flow rate 3.4 mL / min, column temperature 35°C). 1 H NMR (400 MHz, CD3OD) δ 8.31 (s, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 6.06 (s, 2H), 5.50 - 5.37 (m, 1H), 4.98 (s, 1H), 4.20 (s, 3H), 3.98 - 3.79 (m, 4H), 3.12 - 2.99 (m, 1H), 2.88 - 2.76 (m, 2H), 2.36 (s, 3H), 2.26 - 1.96 (m, 4H), 1.84 - 1.47 (m, 6H).
[0246] Compound 16-P2 has a relatively short retention time: LC-MS(ESI) m / z = 571.3 [M + H] + Chiral SFC analysis, retention time 1.601 minutes, chiral purity 99.8% (column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, mobile phase: A is CO2, B isopropanol (0.1% isopropylamine), flow rate 3.4 mL / min, column temperature 35°C). 1 H NMR (400 MHz, CD3OD) δ 8.31 (s, 1H), 7.82 (d, J = 8.6 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 6.13 - 5.99 (m, 2H), 5.50 - 5.40 (m, 1H), 4.98 (s, 1H), 4.20 (s, 3H), 3.98 - 3.76 (m, 4H), 3.11 - 2.97 (m, 1H), 2.87 - 2.76 (m, 2H), 2.36 (s, 3H), 2.27 - 1.96 (m, 4H), 1.85 - 1.46 (m, 6H).
[0247] Example 17 5-((6-(5-(((5-fluoro-4-(((S)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (17) [ka]
[0248] Compound 17 was prepared according to the preparation method in Example 8, and SFC chiral preparative separation of compound 17 was performed (separation conditions: SFC chiral preparative column ChiralPak IH (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is isopropanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 17-P1 and 17-P2.
[0249] Compound 17-P1 has a relatively short retention time, and its LC-MS(ESI) m / z ratio is 555.3 [M+H]. + Chiral SFC analysis was performed with a retention time of 1.282 minutes and a chiral purity of 95.8% (column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, mobile phase: A is CO2, B is isopropanol (0.1% isopropylamine), flow rate 3.4 mL / min, column temperature 35°C). 1 H NMR (400 MHz, CD3OD) δ 8.21 (d, J = 2.7 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 6.03 (d, J = 2.8 Hz, 2H), 5.51 - 5.40 (m, 1H), 4.98 (s, 1H), 4.20 (s, 3H), 4.03 - 3.76 (m, 4H), 3.12 - 2.98 (m, 1H), 2.88 - 2.74 (m, 2H), 2.36 (s, 3H), 2.28 - 1.97 (m, 4H), 1.86 - 1.46 (m, 6H).
[0250] Compound 17-P2 has a relatively long retention time, with LCMS(ESI) m / z = 555.3 [M+H]. + Chiral SFC analysis was performed for 1.504 minutes, with a chiral purity of 99.9% (column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, mobile phase: A is CO2, B is isopropanol (0.1% isopropylamine), flow rate 3.4 mL / min, column temperature 35°C). 1 H NMR (400 MHz, CD3OD) δ 8.21 (d, J = 2.7 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.39 (d, J = 8.6 Hz, 1H), 6.03 (s, 2H), 5.47 - 5.40 (m, 1H), 4.98 (s, 1H), 4.20 (s, 3H), 3.97 - 3.77 (m, 4H), 3.11 - 3.00 (m, 1H), 2.84 - 2.76 (m, 2H), 2.37 (s, 3H), 2.29 - 1.98 (m, 4H), 1.89 - 1.47 (m, 6H).
[0251] Example 18 5-((6-(5-(((5-chloro-4-(((S)-tetrahydrofuran-3-yl)oxy)pyrimidine-2-yl)oxy)methyl)-1-methyl-1H-1,2,3-triazole-4-yl)-2-methylpyridine-3-yl)oxy)octahydrocyclopentadiene-1-carboxylic acid (18) [ka]
[0252] Compound 18 was prepared according to the preparation method in Example 8, and SFC chiral preparative separation of compound 18 was performed (separation conditions: SFC chiral preparative column ChiralPak IH (250 mm × 30 mm, 10 μm), mobile phase: A is CO2, B is isopropanol (0.1% aqueous ammonia)), the corresponding components were collected, and concentrated under reduced pressure to obtain compounds 18-P1 and 18-P2.
[0253] Compound 18-P1 has a relatively short retention time, and chiral SFC analysis: LC-MS (ESI) m / z = 571.2 [M + H] + The retention time was 1.328 minutes, and the chiral purity was 99.9% (column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, mobile phase: A is CO2, B is isopropanol (0.1% isopropylamine), flow rate 3.4 mL / min, column temperature 35°C). 1 H NMR (400 MHz, CD3OD) δ 8.31 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 6.06 (s, 2H), 5.50 - 5.39 (m, 1H), 4.98 (s, 1H), 4.20 (s, 3H), 3.97 - 3.77 (m, 4H), 3.10 - 2.98 (m, 1H), 2.87 - 2.77 (m, 2H), 2.36 (s, 3H), 2.29 - 1.98 (m, 4H), 1.86 - 1.68 (m, 3H), 1.65 - 1.48 (m, 3H).
[0254] Compound 18-P2 has a relatively long retention time, with LC-MS(ESI) m / z = 571.2 [M+H]. + Chiral SFC analysis was performed with a retention time of 1.597 minutes and a chiral purity of 99.8% (column: Chiralpak IH-3, 0.46 cm ID × 50 mm, 3 μm, mobile phase: A is CO2, B is isopropanol (0.1% isopropylamine), flow rate 3.4 mL / min, column temperature 35°C). 1H NMR (400 MHz, CD3OD) δ 8.31 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 6.11 - 6.00 (m, 2H), 5.47 - 5.42 (m, 1H), 4.99 - 4.96 (m, 1H), 4.20 (s, 3H), 3.96 - 3.77 (m, 4H), 3.09 - 2.98 (m, 1H), 2.88 - 2.79 (m, 2H), 2.36 (s, 3H), 2.27 - 1.98 (m, 4H), 1.87 - 1.66 (m, 3H), 1.64 - 1.47 (m, 3H).
[0255] Biological Tests Test Example 1: Testing of the antagonistic properties of a compound In this disclosure, the antagonistic properties of the compound were measured by FLIPR (fluorescence imaging plate reader) and found that the compound is an inhibitor of intracellular calcium elevation induced by hLPAR1 (human lysophosphatidic acid receptor 1) activation expressed in CHO-K1 cells (Chinese hamster ovary cell K1, HDB).
[0256] 1. Experimental reagents and equipment consumables [Table 1]
[0257] 2. Preparation of reagents 2.1. Reaction buffer: HBSS + 20 mM HEPES + 0.1% fatty acid-free BSA + 0.001% F-127 2.2, 50× Red dye: (Red dye for blocking background signals in cells). For preparation, 4 g of taltrazine and 10.2 g of acid red were weighed and dissolved in 100 mL of H2O. 2.3. Fluo-8 staining mixture: 4 mL of reaction buffer, 32 μL of fluo-8, 320 μL of 50× Red dye, and 40 μL of probenecid.
[0258] 3. Preparation of the compound 3.1. Dissolve LPA in DPBS (containing 0.1% fatty acid-free BSA) to prepare a mother liquor with a concentration of 0.8 μM, dispense it, and store it at -20°C. 3.2 Preparation of compounds awaiting measurement: The compounds awaiting measurement were dissolved in DMSO to prepare a mother liquor with a concentration of 10 mM, which was stored at -20°C. At the time of the experiment, the compounds were first gradient diluted with DMSO (initial concentration 50 μM, 3-fold dilution, 10 points) to prepare a compound solution with a concentration of 200. Then, the compound solution was diluted to a concentration of 5 with reaction buffer and transferred to a 384-well plate (product number #6008590) using Bravo.
[0259] 4. Experimental Procedure 4.1 CHO-K1 / LPA1R cells were cultured in cell medium (F-12 + 10% FBS + 400 μg / mL hygromycin B). 4.2. Once the degree of cell fusion reached 80%, the cells were digested with 0.25% pancreatin. 4.3 When the cell morphology became round, digestion was stopped with medium F-12 (10% FBS), and the cells were counted. Subsequently, the density was reduced to 6.7 × 10⁶ with F-12 (10% FBS). 5 Diluted in a cell suspension at a concentration of cells / mL. 4.4 Cells were added to a 384-well Black cell culture plate using a Multidrop automated dispenser, with 30 μL of cell suspension per well, and cultured in a 37°C, 5% CO2 incubator for 20–24 hours. The culture medium was replaced with serum-free F-12 medium and the cells were starved for 24 hours. 4.5. Dosage measurement experiment of LPA. A 6×LPA gradient dilution solution was prepared using reaction buffer (initial concentration 60 μM, 3-fold dilution, 10 points). The culture medium in a 384-well black cell culture plate was discarded and replaced with reaction buffer. 10 μL of 5% DMSO reaction buffer was added, followed by 10 μL of Fluo-8 staining mixture. The mixture was incubated in the dark at 37°C in a 5% CO2 incubator for 0.5 hours. 4.6. The corresponding program was set up in FLIPR, a 6×LPA gradient solution was added, and the values were read. Data was collected for 2 minutes. 4.7. Obtain the reaction curve from the LPA value, and EC 80 The concentration of LPA was calculated. A 6×LPA solution was prepared and placed in a 384-well plate (product number #6008590), and HPE and ZPE were added at the corresponding positions. HPE (100% effect) is 60 μM LPA, and ZPE (0% effect) is the reaction buffer. 4.8. Compound testing. The culture medium in the 384-well black cell culture plate was discarded and replaced with reaction buffer. After transferring 10 μL of 5× compound solution using Bravo, 10 μL of Fluo-8 staining mixture was immediately added, and the mixture was incubated in the dark for 0.5 hours at 37°C in a 5% CO2 incubator. 4.9. The corresponding program was set up in FLIPR, 6×LPA solution was added, and the values were read. Data was collected for 2 minutes. 4.10. Finally, the IC50 of the compound was calculated by analyzing the output fluorescence counts.
[0260] 5. Experimental results
[0261] [Table 2-1] [Table 2-2]
[0262] Conclusion: The results show that the above compound has excellent LPAR1 inhibitory activity and is applicable as an LPAR1 antagonist for the treatment of LPAR1 target-related diseases.
Claims
1. A compound represented by formula I-a or a medicinal salt thereof, 【Chemistry 1】 Eventually, R 1 is hydrogen, C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 Selected from alkoxy groups, halogens, cyano groups, nitro groups, hydroxyl groups, 3-6 membered heterocyclyl groups, 5-6 membered heteroaryl groups, -O-3-6 membered heterocyclyl groups, and -O-5-6 membered heteroaryl groups, the C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 The alkoxy group, 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group are optionally one or more R groups. 4a Replaced by, R 2 is selected from hydrogen, C 1-6 alkyl group, C 1-6 alkoxy group, hydroxy group, halogen, nitro group, cyano group, amino group, carboxy group, 3- to 6-membered cycloalkyl group, 3- to 6-membered heterocyclyl group, 5- to 6-membered heteroaryl group, -O-3- to 6-membered heterocyclyl group, and -O-5- to 6-membered heteroaryl group, wherein said C 1-6 alkyl group, C 1-6 alkoxy group, 3- to 6-membered cycloalkyl group, 3- to 6-membered heterocyclyl group, 5- to 6-membered heteroaryl group, -O-3- to 6-membered heterocyclyl group, and -O-5- to 6-membered heteroaryl group are optionally substituted with one or more R 4b [[is substituted with,]] R 5 C 1-6 alkyl group, C 1-6 Selected from alkoxy groups, methylenecyclopropyl groups, halogens, nitro groups, and cyano groups, the C 1-6 alkyl group, C 1-6 The alkoxy group, methylenecyclopropyl, is optionally substituted with one or more substituents selected from halogen, hydroxyl, cyano, and nitro groups. Y is selected from oxygen atoms or nitrogen atoms. Ring B is selected from a 5-6 member heteroaryl group, and the 5-6 member heteroaryl group is optionally C 1-6 alkyl group, C 1-6 Substituted with 1 to 3 substituents selected from alkoxy groups, methylenecyclopropyl groups, halogens, nitro groups, and cyano groups, the C 1-6 alkyl group, C 1-6 The alkoxy group and methylenecyclopropyl group are optionally substituted with one or more substituents selected from halogens, hydroxyl groups, cyano groups, and nitro groups. R 3 is hydrogen, C 1-6 alkyl group, C 1-6 Selected from alkoxy groups, 3-6 membered cycloalkyl groups, 3-6 membered heterocyclyl groups, 5-6 membered heteroaryl groups, -O-3-6 membered heterocyclyl groups, -O-5-6 membered heteroaryl groups, hydroxyl groups, halogens, nitro groups, cyano groups, amino groups, and carboxyl groups, the C 1-6 alkyl group, C 1-6 The alkoxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group can be optionally selected as one or more R groups. 4c Replaced by, R 4a Each of these is independently selected from halogen, methyl group, ethyl group, methoxy group, ethoxy group, cyclopropoxy group, and cyclobutoxy group. R 4b Each of these is independently selected from halogen, hydroxyl, oxo, nitro, cyano, and amino groups. R 4c These are, independently, halogen, hydroxyl group, oxo, nitro group, cyano group, amino group, and C 1-6 Alkyl, Halo C 1-6 alkyl group, C 1-6 Alkoxy group, Halo C 1-6 Alkoxy group, C 2-6 Alkenyloxy group, C 2-6 Alkynyloxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 3-6 membered heterocycloalkoxy group, C 3-8 Selected from a cycloalkenyloxy group, a 5-6 membered aryl group, or a 3-6 membered heteroaryl group, A compound represented by formula I-a or a medicinal salt thereof.
2. R 1 is hydrogen, C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 Selected from alkoxy groups, halogens, cyano groups, nitro groups, and hydroxyl groups, the C 1-6 Alkyl alkyl groups, 3-6 membered cycloalkyl groups, C 1-6 The alkoxy group can be one or more R groups of any choice. 4a Replaced by, Preferably, R 1 It is selected from hydrogen, methyl group, trifluoromethyl group, and halogen. R 4a This is as defined in claim 1, A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
3. R 2 is hydrogen, C 1-6 alkyl group, C 1-6 Selected from alkoxy groups, hydroxyl groups, halogens, nitro groups, cyano groups, amino groups, carboxyl groups, and 3-6 membered cycloalkyl groups, the C 1-6 alkyl group, C 1-6 The alkoxy group and the 3-6 membered cycloalkyl group can optionally consist of one or more R groups. 4b Replaced by, Preferably, R 2 is hydrogen, C 1-6 Selected from alkyl groups and halogens, the above C 1-6 Alkyl alkyl groups can be one or more R groups as optional. 4b Replaced by, More specifically, R 2 is C 1-6 Selected from alkyl groups, the C 1-6 Alkyl alkyl groups can be one or more R groups as optional. 4b Replaced by, R 4b This is as defined in claim 1, A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
4. The compound represented by formula I'-a or a medicinal salt thereof, 【Chemistry 2】 Eventually, R 1 , R 2 , R 5 , Y, ring B, R 3 This is as defined in claim 1, A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
5. Y is an oxygen atom. A compound represented by formula I-a according to any one of claims 1 to 4, or a medicinal salt thereof.
6. Ring B is 【Transformation 3】 Selected from, The aforementioned 【Chemistry 4】 C is an optional choice. 1-6 alkyl group, C 1-6 Substituted with 1 to 3 substituents selected from alkoxy groups, methylenecyclopropyl groups, halogens, nitro groups, and cyano groups, the C 1-6 alkyl group, C 1-6 The alkoxy group and methylenecyclopropyl group are optionally substituted with one or more substituents selected from halogens, hydroxyl groups, cyano groups, and nitro groups. A compound represented by formula I-a as described in any one of claims 1 to 5, or a medicinal salt thereof.
7. Ring B is, 【Transformation 5】 Selected from, R 3 * is connected to the end, Preferably, ring B is 【Transformation 6】 Selected from, R 3 * is connected to the end, A compound represented by formula I-a as described in any one of claims 1 to 6, or a medicinal salt thereof.
8. R 3 is hydrogen, C 1-6 alkyl group, C 1-6 Selected from alkoxy groups, 3-6 membered cycloalkyl groups, 3-6 membered heterocyclyl groups, 5-6 membered heteroaryl groups, -O-3-6 membered heterocyclyl groups, and -O-5-6 membered heteroaryl groups, the C 1-6 alkyl group, C 1-6 The alkoxy group, 3-6 membered cycloalkyl group, 3-6 membered heterocyclyl group, 5-6 membered heteroaryl group, -O-3-6 membered heterocyclyl group, and -O-5-6 membered heteroaryl group can be optionally selected as one or more R groups. 4c Replaced by, Preferably, R 3 is hydrogen, C 1-6 alkyl group, C 1-6 Selected from an alkoxy group and a 3- to 6-membered cycloalkyl group, the C 1-6 alkyl group, C 1-6 The alkoxy group and the 3-6 membered cycloalkyl group can optionally consist of one or more R groups. 4c Replaced by, R 4c This is as defined in claim 1, A compound represented by formula I-a according to any one of claims 1 to 7, or a medicinal salt thereof.
9. R 3 is C 1-6 Selected from alkyl groups, the C 1-6 Alkyl groups can consist of one or more R 4c Replaced with, preferably, R 3 R is selected from methyl groups, and the methyl group is one to multiple R 4c Replaced by, R 4c is as defined in claim 1, A compound represented by formula I-a according to any one of claims 1 to 8, or a medicinal salt thereof.
10. R 3 is a trifluoromethyl group, difluoromethyl group, ethyl group, cyclopropyl group, -CH 2 OCH 3 , -CH 2 OCHF 2 , -CH 2 OCH 2 CH 3 , 【Transformation 7】 Selected from, A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
11. R 5 is C 1-6 Selected from alkyl groups, the C 1-6 The alkyl group is optionally substituted with one or more halogens. Preferably, R 5 The methyl group is selected from methyl groups, and the methyl group is optionally substituted with 1 to 3 halogens. A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
12. R 4c Each of these is independently selected from halogen, hydroxyl, oxo, nitro, cyano, and amino groups. Or, R 4c Each of them is independently C 1-6 alkyl group, C 1-6 Selected from alkoxy groups, 3-6 membered cycloalkyl groups, 3-6 membered heterocyclyl groups, and 3-6 membered heterocycloalkoxy groups, Or, R 4c Each of these is independently selected from halogen, methyl group, ethyl group, methoxy group, ethoxy group, cyclopropoxy group, and cyclobutoxy group. Or, R 4c Hello C 1-6 Alkoxy group or halo C 1-6 It is an alkyl group. A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
13. The compound represented by formula I-a is 【Transformation 8】 Selected from, A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
14. The compound represented by formula I-a is 【Chemistry 9】 Selected from, A compound represented by formula I-a as described in claim 1, or a medicinal salt thereof.
15. An isotope-substituted compound of the compound represented by formula I-a according to any one of claims 1 to 14, preferably a deuterium atom substitution. Isotope substitute.
16. A therapeutically effective amount comprising at least one compound represented by formula I-a as described in any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, or an isotope-substituted compound as described in claim 15, and a pharmaceutically acceptable excipient. Pharmaceutical composition.
17. In the preparation of a drug for preventing and / or treating diseases related to LPA1, a compound represented by formula I-a as described in any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, or an isotope substitution as described in claim 15, or a pharmaceutical composition as described in claim 16, use.
18. In the preparation of a drug for preventing and / or treating organ fibrosis degenerative diseases, respiratory diseases, kidney diseases, liver diseases, inflammatory diseases, nervous system diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, pain, urinary tract diseases, eye diseases, metabolic diseases, cancer, and transplant organ rejection, the compound represented by formula I-a as described in any one of claims 1 to 14 or a pharmaceutically usable salt thereof, or the isotope substitution described in claim 15 or the pharmaceutical composition described in claim 16, use.
